



LucidQuest Intelligence
Accelerate your success



EADV 2025 Preview – Table of Contents

• <u>General Overview and Conference Themes</u>	<u>3-5</u>
• <u>Noteworthy Scientific presentations at EADV'25</u>	<u>6-83</u>
• <u>Key Topics From Notable Presentations</u>	<u>7-10</u>
• <u>Focus of Key Sponsored Symposia at EADV'25</u>	<u>11-15</u>
• <u>Notable Presentations at EADV'25</u>	<u>16-73</u>
• <u>Key Sponsored Symposia Information</u>	<u>74-83</u>
• <u>Noteworthy AI / ML Presentations</u>	<u>84-97</u>
• <u>Key AI / ML Themes</u>	<u>85-87</u>
• <u>Key AI/ML Presentations Information</u>	<u>88-97</u>
• <u>Get in touch with LucidQuest</u>	<u>98</u>



EADV 2025 – General Overview

- ➔ • **Global Participation & Expertise:** Delegates from across the globe, along with renowned expert speakers, will contribute to advancing dermatology's global discourse
- ➔ • **Comprehensive Scientific Program:** 200+ sessions and 120+ workshops focused on emerging research in dermatology, venereology, immunodermatology, and regenerative medicine
- ➔ • **Industry Advancements:** Numerous global companies will showcase cutting-edge devices, dermatologic technologies, and cosmeceuticals, highlighting the latest innovations in the field
- ➔ • **Pre-Congress Engagement:** Masterclasses on advanced dermatologic treatments to attract clinician participation and enhance practice insights
- ➔ • **Cross-Disciplinary Integration:** Collaboration across dermatologists, immunologists, and plastic surgeons to address multifaceted skin disorders
- ➔ • **Innovation in Treatment Approaches:** Emphasis on immunomodulation and regenerative medicine for skin rejuvenation, aging, and autoimmune diseases





EADV 2025– Conference Themes (1/2)

- **Immunodermatology:** Exploration of immune modulation in skin conditions and novel biologic therapies. Focus on autoimmune and inflammatory skin diseases
- **Skin Aging Mechanisms:** Insights into the impact of systemic inflammation and skin aging, linking immune responses to skin structure
- **Genomic Dermatology:** Advances in genetic research to understand skin diseases at the molecular level, with a focus on precision treatments
- **Regenerative Dermatology:** Stem cells and growth factor therapies will be explored for rejuvenating aging skin and treating chronic dermatological conditions
- **Venereology and Infectious Dermatology:** The spotlight on advances in diagnosing and managing sexually transmitted diseases and related dermatologic conditions





EADV 2025– Conference Themes (2/2)

- **Skin Microbiome:** Research on how microbiota manipulation can optimize dermatologic outcomes and mitigate inflammatory skin conditions
- **Pediatric and Geriatric Dermatology:** Specialized sessions on dermatological care for younger and older populations, focusing on chronic skin conditions and age-related changes
- **Laser and Phototherapy Innovations:** Focus on novel lasers, light therapies, and photodynamic treatments to manage acne, psoriasis, and hyperpigmentation
- **AI in Dermatology:** AI's role in enhancing diagnostic accuracy, predicting treatment responses, and personalizing patient care in dermatology
- **Climate and Dermatology:** The impact of environmental changes on skin health, with a focus on heat stress, pollution, and skin barrier function



Noteworthy Scientific presentations at EADV 2025





Key Topics From Notable Presentations (1/4)

- ✓ • **Hidradenitis Suppurativa (HS):** Key trials evaluating therapies for hidradenitis suppurativa, such as bimekizumab and secukinumab, will be presented. The Phase 3 MIRA study on sonelokimab and real-world data on upadacitinib for HS will be highlighted. Additionally, outcomes from studies on the impact of treatment on quality of life and disease flare rates will be discussed
- ✓ • **Atopic Dermatitis & Chronic Hand Eczema:** Acne treatments will be explored, including results from studies on azelaic acid and laser therapies for post-inflammatory hyperpigmentation. Trials on oral spironolactone and microfocused ultrasound for acne scars will be featured. Rosacea treatments, such as oral probiotics and laser therapies, will be examined in randomized controlled trials
- ✓ • **Vitiligo & Pigmentation Disorders:** Clinical trial data on vitiligo treatments, including ruxolitinib cream in the TRuE-V studies, will be highlighted. Other important trials such as the evaluation of 308 nm excimer laser for lichen planus pigmentosus will be presented. Discussions will cover innovative therapies like depigmenting serum and photobiomodulation therapy for melasma, along with outcomes from studies in skin of color



Key Topics From Notable Presentations (2/4)

- ✓ • **Acne & Rosacea:** Acne treatments will be explored, including results from studies on azelaic acid and laser therapies for post-inflammatory hyperpigmentation. Trials on oral spironolactone and microfocused ultrasound for acne scars will be featured. Rosacea treatments, such as oral probiotics and laser therapies, will be examined in randomized controlled trials
- ✓ • **Prurigo Nodularis, Chronic Pruritus & Urticaria:** Treatment options for prurigo nodularis and chronic pruritus will be discussed, with a focus on biologics such as dupilumab and remibrutinib. Long-term outcomes from the LIBERTY-CSU CUPID trials and the effectiveness of systemic therapies like JAK inhibitors will be presented. Additionally, real-world efficacy studies and psychological burden data for patients with prurigo nodularis will be examined
- ✓ • **Oncology & Skin Cancers:** The latest clinical trial data on skin cancers will be presented, including efficacy results from the BE HEARD EXT and MIRA trials on hidradenitis suppurativa. Other key trials include those assessing cemiplimab for advanced cutaneous squamous cell carcinoma and actinic keratosis treatments with tirbanibulin. The impact of immune checkpoint inhibitors in skin cancers, including melanoma, will be analyzed



Key Topics From Notable Presentations (3/4)



- **Pediatric Dermatology, Wound Healing & Regenerative Medicine:**

This category will focus on pediatric dermatology with studies on the treatment of infantile hemangiomas, including a comparative study on timolol versus occlusive compresses. Regenerative medicine applications such as stem-cell-derived exosomes for alopecia will be explored. Additionally, clinical trial data on wound healing with biologics and laser therapies in pediatric patients will be presented



- **Cosmetic Dermatology, Lasers & Anti-Aging:** Advances in cosmetic dermatology will be presented, focusing on the efficacy of treatments such as fractional lasers, topical products, and devices. Trials on acne, melasma, and skin rejuvenation technologies, including fractional CO2 laser and new dermo-cosmetic formulations, will be discussed. The efficacy of innovative treatments, like hyaluronic acid-based regimens and laser-assisted therapies for acne scars, will be presented in various clinical trials and meta-analyses



- **Alopecia & Hair Disorders:** Key studies on hair loss treatments, including baricitinib and ritlecitinib in alopecia areata, will be showcased. Clinical trials such as the ALLEGRO and BRAVE-AA trials will highlight long-term efficacy and safety data. The role of phototherapy, exosomes, and oral therapies like finasteride and minoxidil will also be explored in managing androgenetic alopecia





Key Topics From Notable Presentations (4/4)



- **Psoriasis & Psoriatic Arthritis:** Efficacy data from the CLEAR-1 and KEEPSAKE studies on biologic therapies like bimekizumab, risankizumab, and guselkumab will be featured for moderate-to-severe psoriasis and psoriatic arthritis. Key insights will be shared from real-world studies on the effectiveness of IL-17 inhibitors and data on cardiovascular risks in psoriasis patients. Psoriatic arthritis outcomes from trials such as BE BOLD and PsABIONd will also be explored



- **Other Autoimmune & Rare Dermatoses:** New therapies and treatment strategies for rare dermatoses like pemphigus vulgaris, Maffucci syndrome, and discoid lupus erythematosus (DLE) will be featured. Key trials include those on rituximab in autoimmune bullous diseases, and the investigation of SIM0711, a novel IRAK4 PROTAC, showing enhanced efficacy in treating rare skin diseases. The PAISLEY CLE Phase 2 trial on deucravacitinib in DLE will also be highlighted



- **Infectious Dermatology:** New therapeutic approaches for infectious dermatologic conditions will be examined, with a focus on treatments for dermatophytosis, onychomycosis, and leprosy. Phase 1 and 2 trials, such as those evaluating methylene blue-mediated photodynamic therapy for warts, will be discussed. The role of antiviral and antifungal treatments in skin infections will be analyzed through recent clinical trials



Focus of Key Industry-Sponsored Sessions at EADV 2025 (1/5)

- **AbbVie:**

- Focus Areas: Psoriasis, Alopecia Areata, Vitiligo
- Sessions will explore advancements in IL-23 modulation in psoriasis, targeting disease pathways in alopecia areata, and innovations in vitiligo treatment

- **Sanofi / Regeneron:**

- Focus Areas: Bullous Pemphigoid & Atopic Dermatitis
- Presentations will focus on innovative treatments for bullous pemphigoid and the future of disease modification in atopic dermatitis

- **Novartis:**

- Focus Areas: Psoriasis & Hidradenitis Suppurativa
- Talks will cover advancements in psoriasis treatments, early intervention opportunities, and new therapies for hidradenitis suppurativa



Focus of Key Industry-Sponsored Sessions at EADV 2025 (2/5)

- **Johnson & Johnson:**

- Focus Areas: Psoriasis Care & Oral Therapies
- Sessions will highlight optimizing psoriasis care, particularly through early intervention, and advancements in oral therapies for better outcomes

- **Kenvue:**

- Focus Areas: Early Skin Care & Regenerative Dermatology
- Focus will be on the science of prejuvenation and the regenerative power of oat-based therapies for skin care

- **Regeneron:**

- Focus Areas: Cutaneous Squamous Cell Carcinoma & CSU
- Discussions will explore new treatment advances for cutaneous squamous cell carcinoma and innovations in managing chronic spontaneous urticaria (CSU)



Focus of Key Industry-Sponsored Sessions at EADV 2025 (3/5)

- **Roche:**

- Focus Areas: Dermatology's Evolving Landscape
- Reflecting on 50 years of dermatology, sessions will address future trends in dermatologic treatments and the global landscape of skin care

- **Boehringer Ingelheim:**

- Focus Areas: Chronic Inflammatory Skin Diseases
- Presentations will delve into the role of neutrophilic inflammation in chronic inflammatory skin diseases and evolving therapeutic strategies

- **Galderma:**

- Focus Areas: Acne, Atopic Dermatitis, Prurigo Nodularis
- Sessions will provide a holistic approach to acne treatment, long-term management of atopic dermatitis, and strategies for treating prurigo nodularis



Focus of Key Industry-Sponsored Sessions at EADV 2025 (4/5)

- **Almirall:**

- Focus Areas: Psoriasis & Atopic Dermatitis
- Focus will be on long-term control strategies in atopic dermatitis and addressing unresolved challenges in psoriasis treatment

- **UCB:**

- Focus Areas: Psoriasis & Hidradenitis Suppurativa
- Discussions will highlight inflammation control as a critical factor in disease modification for both psoriasis and hidradenitis suppurativa

- **Pfizer:**

- Focus Areas: Alopecia Areata
- Presentations will explore clinical insights and advancements in managing alopecia areata, focusing on treatment efficacy and patient perspectives



Focus of Key Industry-Sponsored Sessions at EADV 2025 (5/5)

- **Incyte:**

- Focus Areas: Vitiligo & Atopic Dermatitis
- Sessions will cover the role of ruxolitinib cream in vitiligo and evolving treatment options for moderate atopic dermatitis

- **SkinCeuticals:**

- Focus Areas: Antioxidants in Skin Care
- Presentations will explore the effectiveness of antioxidants like C E Ferulic for improving skin health, aging prevention, and skin longevity

- **Amgen / Kyowa Kirin:**

- Focus Areas: Atopic Dermatitis
- Focus will be on OX40R modulation and new treatment modalities for atopic dermatitis, shaping a new era of therapeutic approaches



Notable Presentations And Late-breaking Sessions At EADV 2025

Notable Presentations Information At EADV 2025

Hidradenitis Suppurativa (HS) (1/5)



Date	Author	Title
17 Sep 2025	Prof. Brian Kirby	The impact of secukinumab on systemic inflammatory markers in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of pooled data from the SUNSHINE and SUNRISE Phase 3 trials
17 Sep 2025	PD Dr. med. Thomas Volz	Baseline Characteristics of Patients with Hidradenitis Suppurativa treated with Secukinumab in a Real-World Setting: Interim Results from the ANIMA Study in Germany
17 Sep 2025	Dr. Afsaneh Alavi	Efficacy of secukinumab uptitration from every 4 weeks to every 2 weeks dosing in week 52 HiSCR non-responder patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE extension trial
17 Sep 2025	Prof. Alexa B. Kimball	The impact of continuous secukinumab treatment through week 104 on patient reported outcomes in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials
17 Sep 2025	Dr. Jennifer Hsiao	The impact of continuous secukinumab treatment between weeks 52–104 on draining tunnels in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE extension trial
17 Sep 2025	Prof. Dr. Jacek Szepietowski	Relationships and sexual health in hidradenitis suppurativa: a post hoc analysis from SUNSHINE and SUNRISE trials
17 Sep 2025	MD, PhD Eva Vilarrasa	Secukinumab-Surgery Combination in Hidradenitis Suppurativa: Favorable Safety and Efficacy Results from a Multicentric Real-World Study
17 Sep 2025	Dr. John R. Ingram	Bimekizumab safety and tolerability in patients with moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT

Notable Presentations Information At EADV 2025

Hidradenitis Suppurativa (HS) (2/5)



Date	Author	Title
17 Sep 2025	Prof. Brian Kirby	Existing and novel measures of hidradenitis suppurativa (HS) flares and symptom exacerbations indicate high levels of disease control with the Nanobody sonelokimab in the Phase 2 MIRA trial
17 Sep 2025	Dr. John R. Ingram	Deep dermal inflammatory lesions (DDILs) drive symptom and quality-of-life burden for patients with moderate-to-severe hidradenitis suppurativa (HS): insights from the MIRA trial population
17 Sep 2025	Dr. Alejandro Molina-Leyva	Bimekizumab shows high long-term efficacy in the treatment of patients with moderate-to-severe hidradenitis suppurativa in real-world clinical conditions: effect on draining tunnels and the importance of combined therapy
17 Sep 2025	Mr. Valdemar Wendelboe Nielsen	Hidradenitis suppurativa among patients with new-onset inflammatory bowel disease - Results from the IBD Prognosis Study
17 Sep 2025	Prof. Alexa B. Kimball	Remibrutinib in patients with moderate to severe hidradenitis suppurativa: Patient-reported outcomes from a randomised, phase 2, double-blind, placebo-controlled platform study
17 Sep 2025	Dr. Ziad Reguiai	Maintenance and Deepening of Clinical Response in Adult Patients With Moderate-to-Severe Hidradenitis Suppurativa Receiving Upadacitinib: Post Hoc Analysis of a Phase 2 Study
17 Sep 2025	Prof. Falk G. Bechara	Remibrutinib in patients with moderate to severe hidradenitis suppurativa: International Hidradenitis Suppurativa Severity Scoring System (IHS4) outcomes from a randomised, phase 2, double-blind, placebo-controlled platform study
17 Sep 2025	Dr. PhD Hessel van der Zee	Improvement of hidradenitis suppurativa (HS)-related quality-of-life impairment with the IL-17A- and IL-17F-inhibiting Nanobody sonelokimab: HiSQOL outcomes in the Phase 2 MIRA trial of patients with moderate-to-severe HS

Notable Presentations Information At EADV 2025

Hidradenitis Suppurativa (HS) (3/5)



Date	Author	Title
17 Sep 2025	Dr. med. Georgios Kokolakis	<u>Impact of continuous secukinumab treatment on flare rates over 2 years in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials</u>
17 Sep 2025	PhD Laurence Lucats	<u>Content Validation of Clinician Reported Outcome instruments utilized in Hidradenitis Suppurativa clinical trials</u>
17 Sep 2025	Dr. med. Georgios Kokolakis	<u>Effectiveness of an implementation strategy to improve screening and diagnosis of patients with hidradenitis suppurativa: Week 24 results of the HELyx implementation science study</u>
17 Sep 2025	Dr. Izadora Lorenza C.M. Lapenda	<u>Efficacy and Safety of Janus Kinase Inhibitors in Moderate to Severe Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis of Randomized Controlled Trials</u>
17 Sep 2025	MD, PhD Eva Vilarrasa	<u>High efficacy and safety of Bimekizumab combined with surgery for hidradenitis suppurativa: Findings from a multicentric study</u>
17 Sep 2025	Mrs. Aameena Ali	<u>Next-Generation Therapies for Hidradenitis Suppurativa: Recent FDA Approvals and a Look at Clinical Trial Landscape</u>
17 Sep 2025	Dr. Muhammad Almahdi	<u>Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Systematic Review and Meta Analysis of RCTs</u>
17 Sep 2025	MD Yozahandy Abarca-Pineda	<u>Efficacy and Safety of Two IL-17 Inhibitors (Bimekizumab and Secukinumab) in the Management of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)</u>

Notable Presentations Information At EADV 2025

Hidradenitis Suppurativa (HS) (4/5)



Date	Author	Title
17 Sep 2025	MD Gianmarco Silvi	<u>Long term efficacy and safety of upatacitinib in hidradenitis suppurativa patients</u>
17 Sep 2025	Dr. Martina L Porter	<u>Povorcitinib for Moderate to Severe Hidradenitis Suppurativa: Week 24 Interim Phase 3 Results</u>
17 Sep 2025	Dr. Kim A. Papp	<u>Efficacy and safety of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa: Week 16 results from a randomised, double-blind, placebo-controlled, multicentre, phase 3 study</u>
17 Sep 2025	Dr. John R. Ingram	<u>Bimekizumab efficacy and safety through 3 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and their open-label extension BE HEARD EXT</u>
19 Sep 2025	Prof. Alexa B. Kimball	<u>A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lutikizumab in Biologic-Naïve Adult Patients With Moderate-To-Severe Hidradenitis Suppurativa</u>
19 Sep 2025	Prof. Brian Kirby	<u>IHS4-100 responses and other IHS4 outcomes with the IL-17A- and IL-17F-inhibiting Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial</u>
19 Sep 2025	Dr. Martina L Porter	<u>Resolution of deep dermal inflammatory lesions with the Nanobody sonelokimab in moderate-to-severe hidradenitis suppurativa (HS): preclinical results and outcomes from the Phase 2 MIRA trial</u>
19 Sep 2025	Dr. Esther García Gil	<u>Safety, Pharmacokinetics, and Pharmacodynamics of LAD191, an IL-1RAP-Targeting Monoclonal Antibody, in Adults with Hidradenitis Suppurativa: Results from Part 3 of a Phase I Study</u>

Notable Presentations Information At EADV 2025

Hidradenitis Suppurativa (HS) (5/5)



Date	Author	Title
19 Sep 2025	Prof. Alexa B. Kimball	<u>Efficacy and safety of brivekimig (a dual-target, anti-tumour necrosis factor and anti-OX40 ligand NANOBODY®-based biologic) in participants with moderate-to-severe hidradenitis suppurativa</u>
19 Sep 2025	Prof. Tzellos Thrasyvoulos	<u>The efficacy of continuous secukinumab treatment over two years, as measured by the International Hidradenitis Suppurativa Severity Scoring System (IHS4), in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials</u>
19 Sep 2025	Prof. Tzellos Thrasyvoulos	<u>Bimekizumab efficacy on IHS4 response levels and draining tunnels by HS disease duration over 2 years: Data from BE HEARD EXT</u>

Notable Presentations Information At EADV 2025

Acne & Rosacea (1/4)



Date	Author	Title
17 Sep 2025	Mrs. Anne-Christin Worthmann	<u>Threefold anti-inflammatory efficacy of a triple combination with salicylic acid, isobutylamido thiazolyl resorcinol and licochalcone a in acne-prone skin</u>
17 Sep 2025	Mrs. Laura Ghanem	<u>Efficacy and safety of oral spironolactone for women with acne vulgaris: A systematic review and meta-analysis of randomized placebo-controlled trials with trial sequential analysis</u>
17 Sep 2025	Evan J. Hohlbein	<u>Development of a Novel Hydrocolloid Patch: Enhanced Absorption and Removability with Demonstrated Tolerability and Efficacy in Acne Vulgaris Subjects with Sensitive Skin</u>
17 Sep 2025	Dr. Aura Vladuti	<u>Dual action of a novel azelaic acid dermo-cosmetic formulation for acne and post-inflammatory hyperpigmentation: Combined evidence from clinical trials</u>
17 Sep 2025	Checrallah James ODEIMI	<u>Efficacy and tolerance of a dermocosmetic cream in facial and truncal acne in a multi-phototype panel: results of a clinical study</u>
17 Sep 2025	Dr. Jinghan Wang	<u>Azelaic Acid-Based Chemical Peeling Combined with Mandelic Acid and Lactic Acid for Mild-to-Moderate Acne Vulgaris: A Randomized Controlled Trial</u>
17 Sep 2025	Dr. Natalia Kovytkina	<u>A randomized, placebo-controlled study evaluating the efficacy of a dermocosmetic serum containing 2-Mercaptionicotinyl Glycine (2MNG) in acne-induced post-inflammatory hyperpigmentation</u>
17 Sep 2025	Dr. Delphine Kerob	<u>Efficacy of a specific dermocosmetic in mild to moderate adult acne: a randomized split-face study in darker phototypes</u>

Notable Presentations Information At EADV 2025

Acne & Rosacea (2/4)



Date	Author	Title
17 Sep 2025	Checrallah James ODEIMI	<u>A dermocosmetic routine as adjunct is highly beneficial in mitigating local treatment-related side effects in mild to very severe acne : results of an observational multicentric study.</u>
17 Sep 2025	Yunfei Ai	<u>Clinical Efficacy of a Ceramides-Containing Salicylic Acid Gel on Acne Management and Skin Barrier Function: A 21-Day Prospective Study</u>
17 Sep 2025	Mrs. Maud LE GUILLOU	<u>Clinical efficacy of Punica granatum ellagitannins in the treatment of acne in adult women</u>
17 Sep 2025	Dr. Aline STENNEVIN	<u>Efficacy and tolerance of a new dermo-cosmetic product containing Silybum Marianum Fruit extract and niacinamide in adults and adolescents with mild to moderate acne</u>
17 Sep 2025	MD Maryam Hekmat	<u>Comparison of the efficacy of topical N-acetyl cysteine versus topical benzoyl peroxide gel in the treatment of patients with moderate acne vulgaris: A double-blind randomized controlled trial</u>
17 Sep 2025	Dr. Hagar El Sayed Abdelghani Anter	<u>Excimer light versus blue light in the treatment of acne, a split face randomized controlled trial</u>
17 Sep 2025	Dr. Glynis Ablon	<u>Once Weekly Topical Treatment with DMT310 Demonstrates Significant and Early Onset of Effect in Patients with Moderate to Severe Acne Vulgaris – Results from the STAR-1 Phase 3 Study</u>
17 Sep 2025	Dr. Narachai Julianon	<u>The Role of Probiotics in Managing Acne Vulgaris: A Systematic Review and Meta-Analysis of Clinical Trials</u>

Notable Presentations Information At EADV 2025

Acne & Rosacea (3/4)



Date	Author	Title
17 Sep 2025	MD Juliano Peruzzo	<u>Rosacea in skin of color: Comparative results from a Brazilian sample</u>
17 Sep 2025	Dr. Panupong Pornsirianant	<u>Efficacy of combined subcision and microfocused ultrasound with visualization for improving atrophic acne scars: A split-face randomized comparative study</u>
17 Sep 2025	Dr. PhD Valérie MENGEAUD	<u>Efficacy and tolerability of a new dermocosmetic serum containing Myrtus communis and Celastrol enriched extracts, azelaic and glycolic acids, in mild to moderate adult female acne</u>
17 Sep 2025	Dr. Sumedha Tirthani	<u>A Randomised Controlled Trial to compare the efficacy of Q-switched Nd:YAG laser with 10% azelaic acid versus Fractional CO2 laser with 10% azelaic acid in the treatment of acne-related Post Inflammatory Hyperpigmentation</u>
17 Sep 2025	MD Dorian Maghsoodloo	<u>Comparison of the efficacy of Q-switched fractional 1064 nm Nd: YAG laser versus long pulse 1064 Nd: YAG laser in the treatment of active facial acne: a double-blind randomized controlled split-face clinical trial</u>
17 Sep 2025	MD Nhan Nguyen	<u>Doxycycline 40 mg vs. DFD-29 40 mg for Rosacea Treatment: A Meta-Analysis of Three Randomized Controlled Trials</u>
17 Sep 2025	Dr. Carolina Ivette Cortes Correa	<u>A Novel Azelaic Acid Cream Targeting Primary and Secondary Symptoms of Papulopustular Rosacea: Results from a Randomized Placebo-Controlled Trial</u>
17 Sep 2025	Cristina Eguren	<u>Efficacy and Safety of Bioth-Ros, a selected oral probiotic mixture, in patients with inflammatory Rosacea: A Randomized Clinical Trial</u>

Notable Presentations Information At EADV 2025

Acne & Rosacea (4/4)



Date	Author	Title
17 Sep 2025	Mrs. Laura Ghanem	Efficacy and safety of oral DFD-29, a low-dose formulation of minocycline versus doxycycline in rosacea: A systematic review and meta-analysis of randomized placebo-controlled trials
17 Sep 2025	Prof. Ben Wang	Efficacy and safety of Magnetic Stimulation in the treatment of erythema of rosacea: a randomized, double-blind clinical trial

Notable Presentations Information At EADV 2025

Atopic Dermatitis & Chronic Hand Eczema (1/9)



Date	Author	Title
17 Sep 2025	MD Judith Corona Herrera	<u>Efficacy of Vitamin D3 in Preventing Chemotherapy-Induced Hand-Foot Syndrome: A Pilot Study</u>
17 Sep 2025	MD David Rosmarin	<u>Long-Term Safety of Ruxolitinib Cream in Pediatric and Adult Patients: an Analysis of 7 Phase 3 Clinical Trials in Atopic Dermatitis and Nonsegmental Vitiligo</u>
17 Sep 2025	Mrs. Yueqiao Liu	<u>Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AK120 in Participants with Moderate to Severe Atopic Dermatitis: Results from a Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial</u>
17 Sep 2025	Prof. Dr. Lauffer Felix	<u>Effectiveness of Upadacitinib in moderate vs. severe atopic dermatitis: interim results</u>
17 Sep 2025	Dr. Yuan Chang	<u>Efficacy and Safety of Benvitimod in Patients with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial</u>
17 Sep 2025	Dr. Padma Mohandas	<u>Clinical trial exit interviews in patients with moderate to severe Chronic Hand Eczema: evaluation of treatment experiences with delgocitinib cream 20 mg/g in the phase 3 DELTA 1 trial</u>
17 Sep 2025	Prof. Dr. Eric Simpson	<u>Raising the Bar of Efficacy in Atopic Dermatitis: Lebrikizumab Maintains Depth of Response Over 3 Years in Week 16 Responders</u>
17 Sep 2025	Dr. Jason Wang	<u>Sustained Improvement in Atopic Dermatitis Disease Control and Treatment Satisfaction With Dupilumab in Clinical Practice: 6-Year Follow-up Results From the RELIEVE-AD Study</u>

Notable Presentations Information At EADV 2025

Atopic Dermatitis & Chronic Hand Eczema (2/9)



Date	Author	Title
17 Sep 2025	Kristen Willard	<u>Toward improvement of global patient and caregiver education in atopic dermatitis: results of an international community survey</u>
17 Sep 2025	Dr. Tarryn Jacobs	<u>Tolerance, efficacy, and quality of life of a dermocosmetic in subjects with atopic dermatitis and skin disorders associated with dryness in South Africa</u>
17 Sep 2025	Dr. med. Yingyu Ding	<u>Antipruritic Efficacy of Azathioprine in Patients with Atopic Dermatitis</u>
17 Sep 2025	Dr. Rebecca Kai Jan Choong	<u>Efficacy and safety of a topical cream containing Lignosus rhinocerus in mild-to-moderate atopic dermatitis: a 6-week split-site pilot study</u>
17 Sep 2025	JiaDe Yu	<u>Delgocitinib cream provides early and meaningful responses in adults with moderate to severe Chronic Hand Eczema: a pooled analysis of the phase 3 DELTA-1 and DELTA-2 trials</u>
17 Sep 2025	MD Lawrence Eichenfield	<u>Delgocitinib cream 20 mg/g in Chronic Hand Eczema patients with skin fissures: efficacy, safety, and pharmacokinetics</u>
17 Sep 2025	MD, PhD Benjamin D. Ehst	<u>Delgocitinib cream leads to significant improvements across all Chronic Hand Eczema signs and region HECSI subscores in the phase 3 DELTA-1 and DELTA -2 trials</u>
17 Sep 2025	MD Robert Bissonnette	<u>Patient reported outcome measures and symptom improvements across subtypes of Chronic Hand Eczema: outcomes from the Phase 3 DELTA-1 and DELTA-2 trials</u>

Notable Presentations Information At EADV 2025

Atopic Dermatitis & Chronic Hand Eczema (3/9)



Date	Author	Title
17 Sep 2025	Mrs. Monaly Ribeiro	<u>Efficacy and Safety of Janus Kinase Inhibitors for Chronic Hand Eczema: A Systematic Review of Randomized Controlled Trials</u>
17 Sep 2025	Dr. Li Zhang	<u>Real-world treatment patterns and effectiveness of abrocitinib in atopic dermatitis: Interim results on Abrocitinib Chinese rEgistry on AD (AHEAD)</u>
17 Sep 2025	MD Andrew Blauvelt	<u>Long-term efficacy with tralokinumab in patients with moderate-to-severe atopic dermatitis: final results from the 5-year ECZTEND study</u>
17 Sep 2025	Mr. Dilip Shingare	<u>Unveiling the Burden and Impact of Flare in Patients With Moderate-to-severe Atopic Dermatitis: Results From the Adelphi Real World Disease Specific Program in Europe</u>
17 Sep 2025	PhD Jungjoong Hwang	<u>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2b Part 1 Study of a Topical GPCR19 Agonist in Patients with Mild-to-Moderate Atopic Dermatitis</u>
17 Sep 2025	Dr. Paolo Calzari	<u>Efficacy and Drug Survival of Tralokinumab in Severe Atopic Dermatitis: A Two-Year Multicenter Study</u>
17 Sep 2025	Dr. Tom Ashton	<u>Serine determines tissue targeted efficacy of PKM2 modulators in atopic dermatitis</u>
17 Sep 2025	Dr. Raquel Dominguez-Lopez	<u>Efficacy and safety of dupilumab in a case series of transplanted patients with severe atopic dermatitis. Shared experience from several hospitals in Spain.</u>

Notable Presentations Information At EADV 2025

Atopic Dermatitis & Chronic Hand Eczema (4/9)



Date	Author	Title
17 Sep 2025	MD Luca Potestio	<u>Efficacy and safety of JAK inhibitors in patients aged >60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study - IL AD (Italian Landscape Atopic Dermatitis)</u>
17 Sep 2025	Prof. Dr. Trinidad Montero-Vilchez	<u>Sustained and rapid efficacy of abrocitinib in atopic dermatitis: A multicenter real-world study with 48-Week follow-up</u>
17 Sep 2025	MD Luca Potestio	<u>Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: Results from a Multicentre, Observational, Retrospective Study</u>
17 Sep 2025	Dr. Supenya Varothai	<u>Efficacy of Ceramide-Containing Moisturizer in Multivesicular Emulsion as a Steroid-Sparing Agent in Patients with Atopic Dermatitis: A Prospective Randomized Controlled Trial</u>
17 Sep 2025	PhD Rashpal Bhogal	<u>Baseline characteristics, and treatment patterns of a Canadian phase IV study (CANDID) of dupilumab for the management of moderate-to-severe atopic dermatitis.</u>
17 Sep 2025	Dr. Araceli Sánchez-Gilo	<u>Multicenter Study of 209 Patients with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab in a Real-World Practice. Efficacy and Safety Data at 52 Weeks</u>
17 Sep 2025	Ms. Duaa Eisa	<u>Ceramide-Containing Moisturiser as Atopic Dermatitis Monotherapy: Clinical Efficacy and Tolerability in Pediatric and Adult Patients</u>
17 Sep 2025	Mrs. Ana Du	<u>Clinical Evaluation of the Efficacy and Tolerance of a Novel Topical Cream for Managing Sensitive, Weakened and Compromised Skin Barrier</u>

Notable Presentations Information At EADV 2025

Atopic Dermatitis & Chronic Hand Eczema (5/9)



Date	Author	Title
17 Sep 2025	Mrs. Maud LE GUILLOU	<u>Clinical efficacy of Ophiopogon japonicus oligofructans on children and adults with atopic dermatitis</u>
17 Sep 2025	MD Marie-Dominique Thouvenin	<u>Tolerance and efficacy of a new emollient "Plus" containing Aquaphilus Dolomiaie and Dextran sodium sulfate extracts in improving long-term atopic skin condition</u>
17 Sep 2025	Mrs. Camille BOUDET	<u>Tolerance and efficacy of an innovative emollient gel containing Aquaphilus Dolomiaie and Dextran sodium sulfate extracts</u>
17 Sep 2025	Mrs. Camille BOUDET	<u>Tolerance and efficacy of a new dermo-cosmetic product containing Aquaphilus dolomiaie and Broussonetia extracts dedicated to pruritus associated with dry skin</u>
17 Sep 2025	Dr. PhD Valérie MENGEAUD	<u>Evaluation of the efficacy of a medical device repairing emollient cream in adults with mild to moderate head and neck atopic dermatitis</u>
17 Sep 2025	Dr. Susanne Abraham	<u>Patients with Atopic Dermatitis in visible Areas have a high Disease Burden and respond well to Treatment with Biologics and JAK Inhibitors: Results from the TREATgermany Registry</u>
17 Sep 2025	PhD Rashpal Bhogal	<u>Baseline characteristics, and treatment patterns of skin of colour patients in a Canadian phase 4 study (CANDID) of dupilumab for the management of moderate-to-severe atopic dermatitis.</u>
17 Sep 2025	Prof. April W. Armstrong	<u>Matching-Adjusted Indirect Comparison of the Efficacy at week 12 of Delgocitinib and topical PUVA in the treatment of Severe Chronic Hand Eczema</u>

Notable Presentations Information At EADV 2025

Atopic Dermatitis & Chronic Hand Eczema (6/9)



Date	Author	Title
17 Sep 2025	Marie-Louise Schuttelaar	<u>Chronic Hand Eczema has a Profound Impact on Daily Life, Social Interactions and Emotional Wellbeing: Results from a Global Patient Survey</u>
17 Sep 2025	Dr. Vimal H. Prajapati	<u>Real-world Effectiveness by Body Regions and Safety of Upadacitinib in Canadian Adult Patients With Atopic Dermatitis who Were Inadequate Responders or Intolerant to Dupilumab: Results From the CAN UpTIMISE Study</u>
17 Sep 2025	Peter Schrader	<u>Safety, tolerability, and pharmacokinetic (PK) results from the single-ascending dose (SAD) portion of the Phase 1 study of BBT001—a novel bispecific IL-4Rα/IL-31 antibody—conducted in healthy volunteers and patients with atopic dermatitis</u>
17 Sep 2025	Apothecom Services	<u>Efficacy of Abrocitinib Flexible Dose Escalation and Reduction Versus Consistent Dosing in Adolescent and Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Real World-Simulating Expanded Access Protocol Study, JADE REAL</u>
17 Sep 2025	Mrs. Sara Filippini	<u>The Impact of Dupilumab on Sleep Quality and Quality of Life in Adults with Atopic Dermatitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials</u>
17 Sep 2025	Dr. Bruno Duarte	<u>Efficacy of Upadacitinib vs Dupilumab Treatment for Moderate to Severe Atopic Dermatitis: Analysis of Time Spent in Response State from the Level Up Study</u>
17 Sep 2025	Prof. Adam Reich	<u>Long-term efficacy and safety of nemolizumab in adolescents with moderate-to-severe atopic dermatitis: Post hoc analyses from ARCADIA LTE 1-year cut-off</u>
17 Sep 2025	Prof. Carsten Flohr	<u>Effectiveness of abrocitinib in patients with atopic dermatitis: results of a federated analysis of real-world evidence in the DREAM TO TREAT AD consortium</u>

Notable Presentations Information At EADV 2025

Atopic Dermatitis & Chronic Hand Eczema (7/9)



Date	Author	Title
17 Sep 2025	Prof. Dr. Diamant Thaçi	<u>Lebrikizumab provides skin clearance and itch relief at week 16 and week 52: pooled results from 2 phase 3 studies ADvocate1 and ADvocate2</u>
17 Sep 2025	Prof. Richard B. Warren	<u>Impact of lebrikizumab in combination with topical corticosteroids in the psychological well-being and depression suspicion in patients with moderate-to-severe atopic dermatitis: a randomized phase 3 clinical study (ADvantage)</u>
17 Sep 2025	Prof. Amy Paller	<u>Safety and Efficacy of up to 3 Years of Dupilumab Treatment in Infants and Children With Severe Atopic Dermatitis</u>
17 Sep 2025	Shuai Xu	<u>Digital Patient-Centered Endpoints of Nocturnal Scratch and Sleep in Patients With Moderate-To-Severe Atopic Dermatitis Treated with Upadacitinib: Results from the Flex Up Wearable Sensor Sub-Study</u>
17 Sep 2025	Apothecom Services	<u>Efficacy and Safety of Abrocitinib Versus Dupilumab in Patients Who Self-Identified as Having Skin of Colour: A Post Hoc Analysis of JADE DARE</u>
17 Sep 2025	Mrs. Anna Sophie Krontoft	<u>Optimising consultations for patients with atopic dermatitis- a clinical controlled trial</u>
17 Sep 2025	PhD Quanzhong Liu	<u>Local Tolerability of Benvitimod Cream 1% Twice Daily in Adults and Children with Atopic Dermatitis: Results from a Phase 3 Randomized Trial</u>
17 Sep 2025	Dr. Leon H Kircik	<u>Interim safety results of amlitelimab (anti-OX40 ligand antibody) in participants with moderate-to-severe atopic dermatitis from the RIVER-AD phase 2/3 ongoing open-label study</u>

Notable Presentations Information At EADV 2025

Atopic Dermatitis & Chronic Hand Eczema (8/9)



Date	Author	Title
17 Sep 2025	Dr. Chih-ho Hong	<u>Effectiveness, Patient-reported Outcomes, and Safety of Upadacitinib in Canadian Adult Patients With Atopic Dermatitis who Were Inadequate Responders or Intolerant to Dupilumab: Results from the CAN UpTIMISE Study</u>
17 Sep 2025	Mrs. Laura Ghanem	<u>Efficacy and safety of ruxolitinib cream monotherapy for atopic dermatitis: An updated systematic review and meta-analysis of randomized vehicle-controlled trials with trial sequential analysis</u>
17 Sep 2025	MD Martin Cevallos Cueva	<u>Safety and efficacy of non-steroidal topical aryl hydrocarbon receptor agonists for the treatment of atopic dermatitis: a systematic review and meta-analysis of randomised controlled trials</u>
17 Sep 2025	PhD Quanzhong Liu	<u>Clinical Efficacy, Safety Profile, and Systemic Exposure of Benvitimod Cream 1% Twice-Daily in Pediatric Atopic Dermatitis: Results from a Phase 3 Trial in China</u>
17 Sep 2025	MD Wei Li	<u>Efficacy and Safety of Abrocitinib in Elderly with Atopic Dermatitis: A Prospective Study</u>
17 Sep 2025	Dr. Andrew E. Pink	<u>Pooled Safety Analysis of Nemolizumab in moderate-to-severe atopic dermatitis: Results from two phase 3 trials</u>
17 Sep 2025	Dr. Vivian Laquer	<u>Nemolizumab treatment did not impair immune response to vaccination in patients with atopic dermatitis – Results from a randomised, double-blind, placebo-controlled study.</u>
17 Sep 2025	Prof. Andrea Bauer	<u>Consensus on core domains for hand eczema trials: Signs, symptoms, control and quality of life</u>

Notable Presentations Information At EADV 2025

Atopic Dermatitis & Chronic Hand Eczema (9/9)



Date	Author	Title
17 Sep 2025	Assoc. Prof. Vered Molho-Pessach	An animated educational video is effective for improving treatment outcomes in pediatric patients with atopic dermatitis: A prospective trial.

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (1/12)



Date	Author	Title
17 Sep 2025	Dr. Steven R. Feldman	<u>Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups (encore)</u>
17 Sep 2025	Dr. Philip Mease	<u>A randomized, double-blind, placebo-controlled Phase 3 clinical trial of sonelokimab—including a risankizumab reference arm—in patients with active psoriatic arthritis and previous inadequate response or intolerance to biologic TNFi therapy (IZAR-2): Study design and rationale</u>
17 Sep 2025	Prof. Yehong Kuang	<u>Efficacy and Safety of Vunakizumab in Psoriasis Patients with Prior IL-17 Inhibitor Failure: A Retrospective Study from China</u>
17 Sep 2025	Dr. PhD Yue Tao	<u>Efficacy and safety of tildrakizumab in the treatment of 32 patients with moderate-to-severe plaque psoriasis</u>
17 Sep 2025	Elena Kolosova	<u>Efficacy of Netakimab in patients with moderate-to-severe plaque psoriasis stratified by BMI: a post-hoc analysis from the phase III PLANETA study</u>
17 Sep 2025	Dr. Joseph F. Merola	<u>Head-to-head study of bimekizumab, an IL-17A/IL-17F inhibitor, and risankizumab, an IL-23 inhibitor, in patients with active psoriatic arthritis: Study design and rationale of BE BOLD, a phase 3b, randomised, parallel-group study</u>
17 Sep 2025	Dr. Kenneth B. Gordon	<u>Achievement of Stringent Skin and Joint Improvements Among Patients With Psoriatic Arthritis and Plaque Psoriasis: A Post hoc Analysis of the KEEPsAKE 1 and KEEPsAKE 2 Phase 3 Studies</u>
17 Sep 2025	Dr. Yue Xiao	<u>The Unsatisfactory Efficacy of Interclass Switching from IL-17A Inhibitor to IL-12/23 Inhibitor</u>

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (2/12)



Date	Author	Title
17 Sep 2025	Prof. Iain McInnes	<u>Impact of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, on skin, nail, and multidomain clinical outcomes in active psoriatic arthritis: results from the randomized, double-blind, placebo-controlled Phase 2 ARGO trial</u>
17 Sep 2025	Prof. Laure Gossec	<u>Effects of sonelokimab, an IL-17A- and IL-17F-inhibiting Nanobody, on patient-reported symptoms and quality of life in psoriatic arthritis: Results from the randomized, double-blind, placebo-controlled Phase 2 ARGO trial</u>
17 Sep 2025	PhD Joanna Dembowy	<u>Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 12-month Results of the PsABIONd Observational Study</u>
17 Sep 2025	PhD Joanna Dembowy	<u>Patient Reported Impact and Satisfaction With Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: 12-month Results of the PsABIONd Observational Study</u>
17 Sep 2025	Prof. Dr. Curdin Conrad	<u>Characteristics influencing secukinumab treatment retention in patients with moderate to severe plaque psoriasis: 5-year real-world results from the SERENA study</u>
17 Sep 2025	Dr. Ying Li	<u>Positive associations between triglyceride-glucose (TyG) and TyG-body mass index (TyG-BMI) with cardiovascular disease in patients with psoriasis: Cross-sectional results from the SPEECH</u>
17 Sep 2025	Prof. Jianzhong Zhang	<u>Real-World Effectiveness and Safety of Secukinumab Among Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Final Results from the UNMASK2 Study</u>
17 Sep 2025	MD NATALIA ARANDA	<u>Efficacy of brodalumab in obese patients with psoriasis: case series in real clinical practice</u>

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (3/12)



Date	Author	Title
17 Sep 2025	Dr. Eingun Song	<u>Safety and Efficacy of Risankizumab in Genital and Scalp Psoriasis in the UnIMMited Phase 4 Randomized Clinical Trial at Week 16</u>
17 Sep 2025	Lilly Immunology	<u>Ixekizumab Demonstrates Continued Improvements in Nail and Scalp Psoriasis through 24 Weeks: Results from the Psoriasis in Special Areas (PSoSA) Study</u>
17 Sep 2025	MD, PhD Alice B. Gottlieb	<u>Ixekizumab Improves Musculoskeletal Symptoms Measured by the IDEOM MSK-8 Questionnaire in Patients with Psoriasis and PEST Scores <3 or ≥3: Results From the Real-World Psoriasis in Special Areas (PSoSA) Study</u>
17 Sep 2025	Prof. Dr. Xiaoyong Man	<u>A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2306 with Secukinumab in Patients with Moderate to Severe Plaque Psoriasis</u>
17 Sep 2025	Dr. med. Ralph von Kiedrowski	<u>Guselkumab shows strong long-term effectiveness and high drug survival in patients with moderate-to-severe psoriasis across different treatment lines – first interim results of the non-interventional German G-REAL study</u>
17 Sep 2025	Dr. MARC PERRUSSEL	<u>Efficacy and tolerability of brodalumab in 42 adult patients with moderate to severe psoriasis: First French real-life case series on hard-to-treat areas</u>
17 Sep 2025	Prof. Dr. Diamant Thaçi	<u>Bimekizumab safety in patients with psoriasis achieving complete skin clearance: 4-year analysis from 5 phase 3/3b trials</u>
17 Sep 2025	Kristina Callis-Duffin	<u>Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: 52-week efficacy and safety results of a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)</u>

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (4/12)



Date	Author	Title
17 Sep 2025	Dr. PhD Carlota Abbad-Jaime de Aragón	<u>Distinct gut microbiota signatures associated with progression of atherosclerosis in psoriasis patients: results from the EDSAP study</u>
17 Sep 2025	PD Dr. med. Andreas Pinter	<u>Incremental medication adherence results in incremental improvement in S-mPASI and Worst Itch scores among patients with mild-to-moderate scalp psoriasis treated with calcipotriol and betamethasone dipropionate cream with PAD technology (CAL/BPD PAD cream) in routine clinical practices in Europe. Results from mixed-effect models in PRO-SCALP study.</u>
17 Sep 2025	Dr. Dr. Bárbara Isamara Rojo Rodríguez	<u>Effectiveness of biologic therapy and its impact on quality of life in patients with moderate to severe psoriasis: real-world results.</u>
17 Sep 2025	MD, PhD Martina Kojanova	<u>Efficacy and survival probability of patients with psoriasis treated with IL-17 inhibitors - bimekizumab, brodalumab, ixekizumab, and secukinumab: Real-world data from the Czech Republic BIOREP registry</u>
17 Sep 2025	Dr. Wolfgang Weger	<u>Effectiveness and safety of tildrakizumab in the treatment of genital psoriasis in Austria, Switzerland, and the Czech Republic (CZATCH-Genital-PsO): 28-week interim results</u>
17 Sep 2025	Prof. Richard B. Warren	<u>Bimekizumab remission and high disease control over 4 years in patients with psoriasis achieving complete skin clearance at Week 16: Results from four phase 3 trials</u>
17 Sep 2025	Dr. Annika Smith	<u>Cardiometabolic Risk in Psoriasis: A Missed Opportunity? Insights from a CVD Prevention Trial Cohort</u>
17 Sep 2025	Mr. Qian Cheng	<u>Super-responders to Xeligekimab in Chinese Patients with Moderate-to-severe Plaque Psoriasis: Clinical Characteristics and Long-term Efficacy in a Post-hoc Analysis of a Phase III Trial</u>

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (5/12)



Date	Author	Title
17 Sep 2025	Mr. Qian Cheng	<u>Efficacy and safety of Xeligekimab in patients with moderate-to-severe plaque psoriasis with cardiovascular and/or metabolic comorbidities: a post-hoc analysis of a phase 3 trial</u>
17 Sep 2025	Mr. Qian Cheng	<u>Efficacy of xeligekimab in patients with moderate-to-severe plaque psoriasis:a post hoc analysis of a randomized,phase 3 trial</u>
17 Sep 2025	Dr. Mathias Tiedemann Svendsen	<u>Greater topical corticosteroid quantity applied reduces severity of psoriasis: Results from randomized controlled trials</u>
17 Sep 2025	Dr. Janet Bachmann	<u>GUIDE Phase 3b trial results: Early intervention with guselkumab results in higher rates of fingernail psoriasis clearance and maintenance of nail response following treatment withdrawal</u>
17 Sep 2025	Mr. Qian Cheng	<u>Efficacy of Xeligekimab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis Previously Treated with TNFi: A Post-hoc Analysis of a Phase III Study</u>
17 Sep 2025	Dr. Baogang Wei	<u>Efficacy and safety of switching biological agents to Vunakizumab in patients with plaque psoriasis: a multicenter prospective observational study</u>
17 Sep 2025	Dr. Daniel Sánchez Báez	<u>Assessment of the safety and efficacy of ixekizumab in patients with psoriasis: a single-centre retrospective study</u>
17 Sep 2025	Prof. Min Zheng	<u>Efficacy of Guselkumab through 48 weeks in Chinese Psoriasis Patients with and without Metabolic Comorbidities: a Post-Hoc Analysis of a Phase 4 RCT</u>

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (6/12)



Date	Author	Title
17 Sep 2025	MD Julia Suttorp	<u>Efficacy of Tildrakizumab in Psoriasis patients - data from a real-world study over three years</u>
17 Sep 2025	Prof. Dr. Matthias Augustin	<u>Assessing tildrakizumab's effectiveness in psoriasis patients with baseline joint pain: interim results from the POSITIVE study</u>
17 Sep 2025	Dr. Steven R. Feldman	<u>Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with plaque psoriasis in a community setting: efficacy and safety results from a phase 4 multicenter, randomized, double-blinded, placebo-controlled study (ARTISTYK)</u>
17 Sep 2025	Prof. April W. Armstrong	<u>Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with plaque psoriasis: patient-reported outcomes in a phase 4 multicenter, randomized, double-blinded, placebo-controlled study (ARTISTYK)</u>
17 Sep 2025	Dr. Ziad Reguiat	<u>Real-world efficacy of brodalumab in psoriasis patients with risk factors for treatment challenges: insights from the PSO-TARGET cohort</u>
17 Sep 2025	Dr. Laura Jane Savage	<u>Long-term effectiveness of secukinumab in patients with moderate to severe plaque psoriasis in the real-world setting: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)</u>
17 Sep 2025	Dr. med. Dennis Niebel	<u>Effectiveness and treatment satisfaction with Tildrakizumab 200 mg in routine clinical practice: 28 weeks interim results from the TIL-TWO study</u>
17 Sep 2025	Dr. med. Georgios Kokolakis	<u>Needs and treatment expectations of elderly patients with moderate to severe psoriasis treated with tildrakizumab in routine clinical practice: week 28 interim results on patients' needs and wellbeing</u>

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (7/12)



Date	Author	Title
17 Sep 2025	MD Elia Rosi	<u>Prospective single-center study on efficacy and safety of ustekinumab biosimilar: short term results</u>
17 Sep 2025	Dr. Irina Vladimirova	<u>Psoriasis and Obesity. Long-Term Efficacy of the IL-23 Inhibitor Guselkumab: A Real-World Experience</u>
17 Sep 2025	Prof. Yehong Kuang	<u>Tildrakizumab in Real-World Chinese Psoriasis: Efficacy-Safety Profiles from a 28-Week Prospective Cohort with Geriatric and Metabolic Syndrome Stratification</u>
17 Sep 2025	MD Aleksandra Frątczak	<u>Psoriasis and Early Treatment: The Role of Memory Cells in Long-Term Therapeutic Efficacy</u>
17 Sep 2025	Dr. Daniel Muñoz Barba	<u>"Real-World Efficacy and Safety of Risankizumab in Psoriasis: Insights After Failure of Ustekinumab and Other Biologics"</u>
17 Sep 2025	PhD Michela Curradi	<u>Psychological Well-being of Moderate-to-Severe Plaque Psoriasis Patients Treated with Tildrakizumab in Clinical Practice in Italy: 28 week interim data from the phase IV BLUE Study</u>
17 Sep 2025	Dr. Jie Chen	<u>Efficacy and Safety of Vunakizumab in Scalp Psoriasis :A Case Report of Three Patients</u>
17 Sep 2025	Dr. Yuling Shi	<u>Efficacy of a new IL-23p19 inhibitor picankibart in the treatment of nail psoriasis: a post-hoc analysis of phase 3 CLEAR-1 study</u>

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (8/12)



Date	Author	Title
17 Sep 2025	Prof. Min Zheng	Super-Response to Guselkumab Treatment in Chinese Patients with Moderate-to-Severe Psoriasis: a Post-Hoc Analysis from a Phase 4 RCT
17 Sep 2025	Cheyenne Parente	Efficacy and safety of oral JAK, TYK2 and PDE4 inhibitors in the treatment of chronic plaque psoriasis - a network meta-analysis
17 Sep 2025	MD Duc Van Le	The efficacy and predictors of response to the 150 mg dosing regimen of secukinumab in Vietnamese patients with moderate-to-severe plaque psoriasis: a single-arm clinical trial
17 Sep 2025	Dr. Ines Zaraa	Tildrakizumab significantly improves clinical outcomes in patients with psoriasis in high impact areas: 52-week interim data of the phase IV ZODIPSO study
17 Sep 2025	Dr. Melinda Gooderham	Zasocitinib (TAK-279), an oral, allosteric, selective TYK2 inhibitor, in moderate-to-severe plaque psoriasis: efficacy analysis by baseline characteristics from a randomized phase 2b trial
17 Sep 2025	Mrs. Kimberly Macasevich	Efficacy and Tolerability of Roflumilast Cream 0.3% and Foam 0.3% in Patients With Plaque Psoriasis Involving the Face and/or Genitals: Outcomes From the Phase 3 DERMIS-1/2 and ARRECTOR Trials
17 Sep 2025	Dr. Lin Cai	Bimekizumab efficacy and safety in Chinese patients with moderate to severe plaque psoriasis in the BE SHINING phase 3, multicentre, randomised, double-blinded, placebo-controlled study
17 Sep 2025	MD Robert Bissonnette	Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (9/12)



Date	Author	Title
17 Sep 2025	Emilio de Dios Berna Rico	<u>Biologic therapy induces favorable remodeling and stabilization of coronary subclinical atherosclerosis in patients with psoriasis: results from the EDSAP cohort</u>
17 Sep 2025	Dr. Yuling Shi	<u>Efficacy of picankibart in moderate-to-severe plaque psoriasis patients with scalp psoriasis: a post-hoc analysis of a phase 3, randomized, double-blind trial</u>
17 Sep 2025	Christina Sorbe	<u>Reduction of genital psoriasis symptoms in male and female patients treated with risankizumab – interim results from a real-world study</u>
17 Sep 2025	Prof. Jonathan Barker	<u>Characteristics of Quality-of-Life High Responders With Plaque Psoriasis and High-Impact Site Involvement Treated With Apremilast: A Post Hoc Analysis of the EMBRACE Trial</u>
17 Sep 2025	Kexiang Yan	<u>A Randomized, Double-blind, Vehicle-controlled Phase I Study Evaluating the Safety and Pharmacokinetic Profile of RSS0393 Ointment as a Single and Multiple Dose Ascending Local Dermal Administration in Healthy and Adult Subjects with Psoriasis</u>
17 Sep 2025	Dr. Marina Otten	<u>A standard dataset for the documentation of psoriasis: results of a consensus process for item operationalisation</u>
17 Sep 2025	MD, PhD Álvaro González-Cantero	<u>High-Level Improvements in Psoriasis Area and Severity Index With Icotrokinra in Participants With Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3 ICONIC-LEAD Study</u>
17 Sep 2025	Dr. Angela Y. Moore	<u>SPECTREM: Guselkumab Efficacy Across Multiple High-Impact Sites in Participants with Low BSA, Moderate Psoriasis</u>

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (10/12)



Date	Author	Title
17 Sep 2025	Dr. Ghita Gmira	<u>Nail Psoriasis: Clinical Study and Therapeutic Efficacy</u>
17 Sep 2025	Dr. Joseph F. Merola	<u>Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study</u>
17 Sep 2025	Dr. Ines Zaraa	<u>Tildrakizumab significantly improves nail psoriasis in an interim data of the phase IV ZODIPSO study until 52 weeks</u>
17 Sep 2025	Dr. Ines Zaraa	<u>Tildrakizumab significantly improves scalp psoriasis in an interim data of the phase IV ZODIPSO study until 52 weeks</u>
17 Sep 2025	Dr. Judy Phillips	<u>Safety, Immunogenicity, and Efficacy of Tildrakizumab in Patients With Chronic Plaque Psoriasis: Final Results From the reSURFACE 1 and reSURFACE 2 Long-Term Extension Studies</u>
17 Sep 2025	Dr. Savi Aneja	<u>comparative efficacy of topical methotrexate and topical tazarotene in psoriasis vulgaris</u>
17 Sep 2025	Dr. Cristina Verallo Rowell	<u>Dietary virgin coconut oil demonstrates greater anti-inflammatory activity than corn oil in a phase II pilot transcriptomic study involving psoriatic skin biopsies</u>
17 Sep 2025	Dr. med. Athanasios Tsianakas	<u>Comparison of Brodalumab and Guselkumab in Achieving Complete Skin Clearance and Quality of Life Improvements in Moderate-to-Severe Psoriasis: Results from a Randomized, Double-blind, Multicenter Clinical Trial</u>

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (11/12)



Date	Author	Title
17 Sep 2025	Dr. Annika Smith	<u>Addressing Cardiovascular Risk in Psoriasis: A Return to Basics? Outcomes of a Randomised Controlled Trial</u>
17 Sep 2025	Prof. Zhang Furen	<u>Efficacy and safety of picankibart in patients with psoriasis who had been treated with biologics: a multicenter, open-label phase 2 trial</u>
17 Sep 2025	Dr. Leon H Kircik	<u>Efficacy of zasocitinib (TAK-279), an oral, allosteric, potent and selective TYK2 inhibitor, evaluated by Physician's Global Assessment×Body Surface Area (PGA×BSA), in a randomized phase 2b trial in moderate-to-severe plaque psoriasis</u>
17 Sep 2025	Prof. Richard Langley	<u>Efficacy of Apremilast in Paediatric Patients With Plaque Psoriasis According to Disease Duration in the SPROUT Randomised Controlled Trial</u>
17 Sep 2025	Mr. Sakil Syeed	<u>Understanding patient types prescribed oral advanced therapies or biologics for psoriasis: Results from a real-world survey in Germany</u>
17 Sep 2025	Christina Sorbe	<u>Real-world outcomes and drug survival of brodalumab: Results from the German Psoriasis Registry PsoBest</u>
17 Sep 2025	Dr. Yuling Shi	<u>Efficacy of picankibart in genital psoriasis: results from the phase 3 randomized, double-blind CLEAR-1 study</u>
17 Sep 2025	Dr. Yuling Shi	<u>Efficacy of Picankibart in Moderate-to-Severe Plaque Psoriasis Between Biologic-Experienced and Biologic-Naive Patients: A 52-Week results from the Phase 3 CLEAR-1 Study</u>

Notable Presentations Information At EADV 2025

Psoriasis & Psoriatic Arthritis (12/12)



Date	Author	Title
17 Sep 2025	Dr. Ines Zaraa	Tildrakizumab significantly improves genital psoriasis in an interim data of the phase IV ZODIPSO study until 52 weeks

Notable Presentations Information At EADV 2025

Vitiligo & Pigmentation Disorders (1/4)



Date	Author	Title
17 Sep 2025	Dr. med. Alireza Jafarzadeh	<u>A Systematic Review of Case Series and Clinical Trials Investigating Regenerative Medicine for the Treatment of Vitiligo</u>
17 Sep 2025	Prof. Xiaofei Zhu	<u>Effect of High-Frequency 308nm Excimer Light Therapy on Repigmentation Speed in Vitiligo: A Randomized Controlled Clinical Trial</u>
17 Sep 2025	Prof. Jing Ma	<u>Efficacy Observation of Micrograft Transplantation Combined with NB-UVB in the Treatment of Stable Disseminated Vitiligo</u>
17 Sep 2025	Dr. Kiruthika Subburaj	<u>A prospective randomized trial comparing post-surgical topical application of basic fibroblast growth factor versus combination of tacrolimus and basic fibroblast growth factor versus tacrolimus monotherapy in stable vitiligo patients following non cultured epidermal cell suspension procedure</u>
17 Sep 2025	Mrs. Nour Ghostine	<u>Red Light Therapy for post-inflammatory hyperpigmentation and melasma: A systematic review of its efficacy, safety, and clinical applications</u>
17 Sep 2025	MD Ana-Maria Toma	<u>Familial Vitiligo Post-SARS-CoV-2: Insights into Viral-Induced Autoimmunity and Excimer Laser Efficacy</u>
17 Sep 2025	MD Dorian Maghsoodloo	<u>Efficacy, safety, tolerability and treatment durability of microneedling plus topical tranexamic acid in combination with topical modified Kligman lightening formula for melasma: A four-arm assessor and analyst blinded randomized controlled clinical trial</u>
17 Sep 2025	Mrs. Ana Carolina Putini Vieira	<u>Comparative efficacy and safety of botanical extracts and hydroquinone for melasma: a systematic review</u>

Notable Presentations Information At EADV 2025

Vitiligo & Pigmentation Disorders (2/4)



Date	Author	Title
17 Sep 2025	Dr. PhD Tomoko Kobayashi	<u>Efficacy and Safety of Combination Therapy with Intense Pulsed Light and 1927-nm Non-Ablative Fractional Laser for Melasma in Japanese Patients: A Retrospective Study</u>
17 Sep 2025	MD, PhD Jung Min Bae	<u>Efficacy of Vitamin C, E, and Ferulic Acid Serum for Managing Post-Excimer Laser Hyperpigmentation in Patients with Facial Vitiligo</u>
17 Sep 2025	MD Yu-Wen Huang	<u>Efficacy and Safety of Modified Laser-assisted Suction Blister Epidermal Grafting (m-SBEG) in Stable Vitiligo Vulgaris: A Long-term Follow-up Study of 296 Patients</u>
17 Sep 2025	Dr. Baiyu LI	<u>An investigation evaluating the efficacy of a 2-MNG-containing serum on improving skin tone and hyperpigmentation: results of 2 clinical studies</u>
17 Sep 2025	Dr. Delphine Kerob	<u>Efficacy and tolerability of a 2-MNG-containing serum in the treatment of facial solar lentigo over 3 months of daily applications</u>
17 Sep 2025	Dr. Delphine Kerob	<u>Randomized controlled investigator-blinded comparative study of the efficacy and tolerability of a new 2-MNG containing serum versus Cysteamine 5% in the treatment of melasma</u>
17 Sep 2025	Dr. Rana Abdul Kadiru	<u>Efficacy of Topical Timolol 0.5% in the Treatment of Post-Acne Erythema: A Pilot Study in Ten Patients</u>
17 Sep 2025	Mrs. Qian Yu	<u>A Randomized, Split-Lesion Controlled Study to Evaluate the Efficacy and Safety of 308 nm Excimer Lamp Combined with Compound clobetasol propionate Cream in the Treatment of Stable Vitiligo</u>

Notable Presentations Information At EADV 2025

Vitiligo & Pigmentation Disorders (3/4)



Date	Author	Title
17 Sep 2025	Mrs. Heike Foelster	Reducing Hidden Spots: A Vehicle-Controlled Study on the Efficacy of Thiamidol for Managing Subclinical Hyperpigmentation
17 Sep 2025	Dr. Ni Zeng	Comparative Effectiveness of Photobiomodulation Therapy (PBMT) Combined with Cord Blood-Derived Platelet-Rich Plasma or Picosecond Laser for Melasma: A Prospective Split-Face Clinical Trial
17 Sep 2025	Dr. Amit G Pandya	Efficacy and Safety of Ruxolitinib Cream Combined With NB-UVB Phototherapy for Treatment of Vitiligo
17 Sep 2025	Prof. Dr. Thierry Passeron	Characterization of Vitiligo and Repigmentation Response by Lesion Extent and Distribution: Subgroup Analyses From the Ruxolitinib Cream Phase 2 TRuE-V Mechanism of Action Study
17 Sep 2025	Dr. med. Alireza Jafarzadeh	Efficacy and Safety of Small Molecule Inhibitor Therapies for Vitiligo: A Systematic Review in Adults, Adolescents, and Children
17 Sep 2025	Dr. Supachak Smitthisakda	Efficacy of 1064-nm picosecond laser in the treatment of lichen planus pigmentosus: a split-face randomized controlled trial
17 Sep 2025	Dr. Yiwen Yang	Evidence from China: efficacy and tolerability of a depigmenting serum containing Isobutylamido-thiazolyl-resorcinol (Thiamidol) as a monotherapy or an adjunctive treatment for hyperpigmentation
17 Sep 2025	Dr. Nagbhushan Hegde	Assessing the efficacy of Microneedling with Tranexamic acid as an adjuvant to conventional therapy in the treatment of melasma: A Split face Double blinded Randomised Control Trial

Notable Presentations Information At EADV 2025

Vitiligo & Pigmentation Disorders (4/4)



Date	Author	Title
17 Sep 2025	Prof. Dr. Thierry Passeron	An Open-Label, Phase 2, Safety and Efficacy Study of Ruxolitinib Cream in Patients With Genital Vitiligo
17 Sep 2025	Meghna Varambally	Reporting of Skin Color in Randomized Controlled Trials on Vitiligo: A Systematic Review
17 Sep 2025	Dr. PhD Hawasatu Dumbuya	Efficacy of a 2-MNG-Containing Serum and Sunscreen Regimen on Improving Facial-Dyschromia in Skin of Color Women
17 Sep 2025	Mrs. Miho Tanaka	Efficacy and tolerability of a moisturizer containing a synergistic blend of bioactive ingredients in treating hyperpigmentation including post-inflammatory hyperpigmentation.
18 Sep 2025	Dr. Leandro L. Santos	Prevalence and Clinical Characteristics of Vitiligo-Associated Hearing Loss Among Patients Enrolled in a Phase 2 Clinical Trial of Povorcitinib
18 Sep 2025	Prof. Dr. Antoine Bertolotti	Afamelanotide: A Novel Promising Treatment for Vitiligo Case Studies from the Randomized CUV105 Clinical Trial

Notable Presentations Information At EADV 2025

Alopecia & Hair Disorders (1/4)



Date	Author	Title
17 Sep 2025	Prof. Dr. Thierry Passeron	<u>Baricitinib provides higher efficacy in adolescents relative to adults with alopecia areata despite more severe disease at baseline: 36-week outcomes from BRAVE-AA trials.</u>
17 Sep 2025	Dr. Maryanne M. Senna	<u>Characterizing loss of response occurring in a small number of patients during long-term maintenance therapy with baricitinib 4 mg: Results from BRAVE-AA1 and -AA2 trials</u>
17 Sep 2025	PhD Alexandre Lejeune	<u>Updated integrated safety analysis of ritlecitinib up to ~5 years in patients with alopecia areata (AA) from the ALLEGRO clinical trial program</u>
17 Sep 2025	Dr. Maria Naseer Memon	<u>Efficacy of topical finasteride 0.25% with minoxidil 5% vs. Topical minoxidil 5% alone in treatment of male pattern androgenic alopecia</u>
17 Sep 2025	MD, PhD bedoui farah	<u>A Randomized Controlled Trial to Determine the Effectiveness of Low-Level Laser Therapy for Androgenetic Alopecia</u>
17 Sep 2025	Mrs. María José Gómez	<u>Impact of a Novel Dietary Supplement on Efficacy of Pharmacological Treatments for Androgenic Alopecia: A real-life multicenter randomized assessor-blinded trial.</u>
17 Sep 2025	PhD Byong S. Cho	<u>The efficacy and safety of adipose stem cell-derived exosomes in severe alopecia areata</u>
17 Sep 2025	Dr. Hamed Zartab	<u>Assessing safety and efficacy of a mixture of oral finasteride 1 mg, minoxidil 1 mg, and biotin 5 mg in treatment of androgenetic alopecia in males: a single-arm, before-after clinical trial</u>

Notable Presentations Information At EADV 2025

Alopecia & Hair Disorders (2/4)



Date	Author	Title
17 Sep 2025	Dr. Suparuj Lueangarun	<u>Efficacy of Rose Stem Cell-Derived Exosomes (RSCEs) Combined with Fractional Picosecond Laser (FPL) for the Treatment of Male Androgenetic Alopecia (AGA)</u>
17 Sep 2025	Prof. Yu-Ping Ran	<u>Efficacy and Toleration of Baricitinib in Severe Alopecia Areata Patients: A Retrospective Real-World Study</u>
17 Sep 2025	Prof. Bianca Maria Piraccini	<u>Topical finasteride for androgenetic alopecia: real-world 12-month efficacy and safety data in 120 patients</u>
17 Sep 2025	Dr. Helen Tran	<u>Pediatric clinical trial program in progress: A phase 3 study and long-term extension study to evaluate the efficacy and safety of ritlecitinib in children 6 to <12 years of age with severe alopecia areata</u>
17 Sep 2025	PhD Byong S. Cho	<u>The Efficacy and Safety of ASC-Exosomes (ASCE) in Androgenetic Alopecia based on the Translational Study including Preclinical and Clinical Study</u>
17 Sep 2025	PD Dr. med. Katarzyna Osipowicz	<u>Efficacy of Picosecond Laser Treatment in Improving Hair Thickness and Density in Patients with Alopecia</u>
17 Sep 2025	Mrs. Laura Ghanem	<u>Comparison of single-spin to double-spin platelet-rich plasma (PRP) centrifugation methods in the treatment of androgenic alopecia: A systematic review and meta-analysis of randomized controlled trials</u>
17 Sep 2025	Prof. Jianzhong Zhang	<u>Efficacy and safety of Jaktinib tablet in Chinese adults with severe alopecia areata: a randomized, double-blind, multi-center, phase 3 trial</u>

Notable Presentations Information At EADV 2025

Alopecia & Hair Disorders (3/4)



Date	Author	Title
17 Sep 2025	Dr. med. Alireza Jafarzadeh	Efficacy and Safety of Laser Therapy and Phototherapy in Cicatricial and NonCicatricial Alopecia: A Systematic Review Study
17 Sep 2025	Dr. Yulia Romanova	Efficacy of photodynamic therapy with chlorin E6-based photosensitizer for folliculitis decalvans
17 Sep 2025	Dr. Shaikha Alhaj	Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis
17 Sep 2025	Dr. Enovwo Obaro Omatighene	"COMPARATIVE EFFICACY OF PLATELET-RICH PLASMA AND INTRALESIONAL TRIAMCINOLONE In treatment OF ALOPECIA: A PILOT STUDY"
17 Sep 2025	Dr. Anisha Biswal	comparison of efficacy of oral minoxidil 1.25mg vs topical minoxidil 5% in male androgenetic alopecia - a randomized non-inferiority open-label pilot study
17 Sep 2025	Dr. Lamis Elyamani	Efficacy of Tofacitinib in Alopecia Aerata
17 Sep 2025	Dr. Arash Mostaghimi	A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial (UP-AA) To Evaluate Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Study Design and Baseline Patient Characteristics
17 Sep 2025	Dr. Grace Boyd	A multi-centre retrospective study evaluating the real-world efficacy and safety of ritelcitinib in the treatment of alopecia areata.

Notable Presentations Information At EADV 2025

Alopecia & Hair Disorders (4/4)



Date	Author	Title
17 Sep 2025	Dr. Brett King	<u>Long-term efficacy and complete scalp hair regrowth in patients with alopecia areata receiving ritlecitinib 50 mg QD up to 3 years in the ALLEGRO clinical trial program</u>
18 Sep 2025	MD Anusha Pasumarthi	<u>JAK3/TEC Inhibition is Safe and Effective in Cicatricial Alopecias: Evidence from a Prospective Trial</u>
19 Sep 2025	Dr. Brett King	<u>Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials</u>
19 Sep 2025	Dr. Brett King	<u>Rationale and design of a novel, phase 3, external and synthetic placebo-controlled clinical trial of ritlecitinib 50 mg and 100 mg for alopecia areata</u>
19 Sep 2025	Dr. Jerry Shapiro	<u>Comparative Efficacy of an Investigational Oral Minoxidil Extended-Release Tablet Versus Existing Minoxidil Formulations in Androgenetic Alopecia: A Blinded Retrospective IGA Analysis</u>
19 Sep 2025	Wenyu Wu	<u>Evaluating the Efficacy and Safety of Deucravacitinib in Refractory Lichen Planopilaris: A Single-Center Retrospective Pilot Study</u>

Notable Presentations Information At EADV 2025

Cosmetic Dermatology, Lasers & Anti-Aging (1/4)



Date	Author	Title
17 Sep 2025	PhD Gwendal Josse	<u>Evaluation of the efficacy of a new dermo-cosmetic product containing Silybum Marianum Fruit extract and niacinamide in young acne adults: focus on acne lipid profile</u>
17 Sep 2025	PhD Monika Pasikowska-Piwko	<u>A Novel Melanogenesis Inhibitor Demonstrates Safety and Efficacy in in vitro and Human in vivo Studies</u>
17 Sep 2025	Dr. Suparuj Lueangarun	<u>Efficacy of Silicone Gel vs. Control Moisturizer in Reducing Downtime Following Fractional Energy-Based Device Treatment in Patients with Fitzpatrick Skin Types III-V: A Split-Face, Randomized Pilot Study</u>
17 Sep 2025	Mrs. Lydia Picazo Garcia	<u>Efficacy and tolerance study of a cosmetic plant-based body oil</u>
17 Sep 2025	Mrs. MERCEDES ABARQUERO	<u>Benefit of incorporating a serum with hyaluronic acid and proxylane in a microneedle radiofrequency procedure: results of skin aging assessment by dermatological ultrasound</u>
17 Sep 2025	Dr. Nancy Emmanuel	<u>Efficacy of 532 nm KTP Laser Therapy for Different Subtypes of Facial Vascular Lesions: A Systematic Review and Meta-Analysis</u>
17 Sep 2025	Jaimie Jerome	<u>Skin Barrier Cream: Evaluation of the Efficacy and Tolerance of a Lightweight Barrier Cream on Barrier Improvement in Dry Skin and Non-Ablative Laser Skin</u>
17 Sep 2025	Dr. Baiyu LI	<u>A clinical study on the efficacy and safety of a panthenol-containing sunscreen using post-photorejuvenation procedure</u>

Notable Presentations Information At EADV 2025

Cosmetic Dermatology, Lasers & Anti-Aging (2/4)



Date	Author	Title
17 Sep 2025	Dr. Hua Wang	<u>Comprehensive Evaluation of the Efficacy and Safety of a Novel Multi-Component Topical Anti-Aging Eye Cream</u>
17 Sep 2025	Dr. Natalia Kovyilkina	<u>A novel co-bonding technology combining Grifola frondosa extract, peptides (Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7, M3K) and rhamnose stimulates the gene and protein expression of different collagens in fibroblasts: results from an in vitro study</u>
17 Sep 2025	Mrs. Durand Nadège	<u>Triple Collagen Activation for Visible Skin Rejuvenation: an upgraded formulation with scientific and clinically proven efficacy.</u>
17 Sep 2025	MD, PhD Xi Yan	<u>Anti-Glycation and Anti-Aging Efficacy of A New Flavo-Proxylane Cream in a Novel Ex Vivo Skin Model</u>
17 Sep 2025	Mrs. Laura Fagundes	<u>Evaluating cleansing efficacy: development and evaluation of renewing antioxidant cleansing gel</u>
17 Sep 2025	MD Amir Moradi	<u>Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post- Ultrasound Procedure for Subjects Undergoing Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Therapy</u>
17 Sep 2025	Dr. Julia Gallinger	<u>Efficacy and Tolerability of an Anti- Aging Routine Including an Epicelline Containing Serum in Combination with a Day Cream with SPF 30 Containing Two Molecular Sizes of Hyaluronic Acid and Glycine Saponin and a Night Cream with Two Molecular Sizes of Hyaluronic Acid and Dexpanthenol.</u>
17 Sep 2025	Mrs. Mencía Hermosa	<u>Comparative study to evaluate the efficacy and tolerance of a new barrier-function gel serum in strengthening the skin barrier during a retinization treatment</u>

Notable Presentations Information At EADV 2025

Cosmetic Dermatology, Lasers & Anti-Aging (3/4)



Date	Author	Title
17 Sep 2025	Dr. Maissa Abid	<u>Assessment of Fractional CO2 Laser Efficacy in Treating Acne Scars: Results from 23 Cases</u>
17 Sep 2025	Dr. Patchareya Mekasuwandit	<u>A prospective, split-face, randomized controlled trial comparing efficacy and safety between depth of fractional 1064 nm Nd:YAG picosecond laser for enlarged pore treatment in Asians</u>
17 Sep 2025	Dr. Arini Widodo	<u>Efficacy of Intensive, Short-Term Acoustic Wave Treatment (AWT) for Abdominal Circumference and Fat Reduction: A Case Series</u>
17 Sep 2025	Dr. med. Alireza Jafarzadeh	<u>Evaluation of the efficacy, safety, and satisfaction rate of topical latanoprost in patients with hypopigmented burn scars treated with fractional CO2 laser: a double-blind randomized controlled clinical trial</u>
17 Sep 2025	Dr. med. Alireza Jafarzadeh	<u>Evaluation of the Efficacy, Safety, and Satisfaction Rates of Platelet-Rich Plasma, Non-Cross-Linked Hyaluronic Acid, and their Combination in Patients with Acne Scars Treated with Fractional CO2 Laser: A Randomized, Double-Blind, Split-Face Comparative Study</u>
17 Sep 2025	MD Irina Poleva	<u>Safety and efficacy of a Novel Amino Acids based injectable gel for lifting effect in cosmetic dermatology: a clinical evaluation</u>
17 Sep 2025	MD Thanasak Kanjanamungsak	<u>Comparative study on the efficacy of application methods of topical Timolol in post-operative ablative fractional carbon dioxide 10,600-nm laser: single-blinded, randomized, controlled clinical trial</u>
17 Sep 2025	Dr. Suparuj Lueangarun	<u>Efficacy of Fractional Picosecond Laser (FPL) Combined with Rose Stem Cell-Derived Exosomes (RSCs) Versus FPL Alone in the Treatment of Acne Scars: A Split-Face Pilot Study</u>

Notable Presentations Information At EADV 2025

Cosmetic Dermatology, Lasers & Anti-Aging (4/4)



Date	Author	Title
17 Sep 2025	Dr. med. Alireza Jafarzadeh	<u>Evaluation of the Efficacy, Safety, and Satisfaction Rates of Platelet-Rich Plasma, Non-Cross-Linked Hyaluronic Acid, and their Combination in Patients with Acne Scars Treated with Fractional CO2 Laser: A Randomized, Double-Blind, Split-Face Study</u>
17 Sep 2025	MD, PhD Olivier Gaide	<u>A randomized phase 2 proof-of-concept study to evaluate the efficacy and safety of topical bimiralisib application in patients suffering from actinic keratosis on the face and/or scalp and/or back of hands over a 2 and 4-week treatment period</u>
17 Sep 2025	Dr. Dennis Roggenkamp	<u>New opportunities in assessing biophysical skin characteristics: results from two real-world-evidence studies using the handheld IoT device Skinly</u>
17 Sep 2025	Marta Furmanczyk	<u>Clinical evaluation of safety and efficacy of the cleansing foam formulated with olive leaf extract, Saccharide isomerate and Lavender flower extract.</u>
17 Sep 2025	Mr. Alexander Schneller	<u>Innovative industrial 3D-Scanning and 3D-Printing Technologies allow for a Reintroducing of three-dimensional Wax Replicas "Moulages" in Dermatology</u>
17 Sep 2025	Dr. PhD Hawasatu Dumbuya	<u>Evaluation of the Performance of Broad-Spectrum Sunscreens Efficacy Using Electrochemistry</u>
18 Sep 2025	Prof. Dr. Ines Verner Rashkovsky	<u>How to achieve natural results</u>
19 Sep 2025	Dr. Valeria Barreto Campos	<u>Medical insights into pre-procedure care: dermo-cosmetic skin preparation for superior results</u>

Notable Presentations Information At EADV 2025

Infectious Dermatology (1/2)



Date	Author	Title
17 Sep 2025	MD Dr. Zainab Mohamed	<u>Comparative Efficacy of Trichloroacetic Acid Combined with Silver Nitrate and Cryotherapy in Treating Planter Warts</u>
17 Sep 2025	MD, PhD Degang YANG	<u>Age and gender disparity among leprosy cases in recent 20 years in Shanghai: results from the leprosy surveillance system</u>
17 Sep 2025	han ma	<u>Efficacy and safety of 0.75% metronidazole gel in patients with mild chronic paronychia: a randomized, double-blind, placebo-controlled trial</u>
17 Sep 2025	Prof. Khadiga Abdelmageed	<u>Combined fractional CO2 laser with topical tioconazole versus Q-switched Nd-YAG laser in the treatment of onychomycosis; a randomized comparative trial</u>
17 Sep 2025	Dr. Zareen Saqib Suleri	<u>efficacy and safety of voriconazole vs itraconazole; a randomized, prospective, comparative, open label clinical trial</u>
17 Sep 2025	Dr. Patricia Anne Nicole Ecarma	<u>A Randomized Controlled Assessor-Blinded Trial of Methotrexate compared to Prednisone in the Management of Hansen's Disease Patients with Type 1 Reaction in a Tertiary Government Hospital</u>
17 Sep 2025	Dr. Luisa Fernanda Martínez Rosas Híjar	<u>Secondary cutaneous blastomycosis; a case resulting from migration.</u>
17 Sep 2025	Dr. Afsana Nahid	<u>Efficacy and safety of terbinafine and itraconazole monotherapy in conventional and increased doses and in combination in dermatophytosis</u>

Notable Presentations Information At EADV 2025

Infectious Dermatology (2/2)



Date	Author	Title
17 Sep 2025	Dr. Swagata Tambe	<u>Assessment of problems faced by Leprosy Patients in Release from Treatment (RFT) Phase</u>
17 Sep 2025	Dr. prachy garg	<u>Beyond the surface: Unlocking enhanced antifungal efficacy through comparison between luliconazole alone and luliconazole with salicylic acid peel synergy in dermatophytosis.</u>
17 Sep 2025	MD, PhD Fatma Badr Yosef Ibrahim Elkomy	<u>Efficacy of Methylene Blue Mediated Photodynamic Therapy for Multiple Common Warts Using Intralesional and Topical Application</u>
17 Sep 2025	Mr. Settanan Plangsiri	<u>Hyalohyphomycosis caused by Diaporthe phaseolorum in a Renal Transplant Recipient with Systemic AL Amyloidosis: A Rare Case Report</u>
19 Sep 2025	Dr. Alyce Mayfosh	<u>Arginine Undecylenate, a Novel Viral Entry Inhibitor, for the Topical Treatment of Herpes Zoster and Associated Pain: A First-in-Patient, Randomized, Double-Blind, Placebo-Controlled Phase Ib Study</u>

Notable Presentations Information At EADV 2025

Oncology & Skin Cancers (1/3)



Date	Author	Title
17 Sep 2025	Dr. Vojtěch Tretera	<u>Comparison of the efficacy and safety between adjuvant and palliative anti-PD-1 treatment of stage IV oligometastatic melanoma</u>
17 Sep 2025	Dr. Yasmine Ben Alaya	<u>Secondary cutaneous lymphoma : A monocentric study results</u>
17 Sep 2025	Dr. med. Kata Czirbesz	<u>Efficacy of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma. Real-life data.</u>
17 Sep 2025	Dr. Gabriele Roccuzzo	<u>Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/ refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT"</u>
17 Sep 2025	MD Josje Mangnus	<u>Development of ulceration and symptoms during active surveillance in patients with basal cell carcinoma: results from a prospective observational multicenter cohort study</u>
17 Sep 2025	Dr. Roland Aschoff	<u>Topical treatment of actinic cheilitis with Tirbanibulin: Results of a monocentric phase II study to investigate efficacy and tolerability</u>
17 Sep 2025	Dr. Rhian Sheppeard	<u>Recurrence rates and Follow- up Outcomes of Pleomorphic Dermal Sarcomas across three Dermatology Departments: Results of an Audit against the UK Guidelines for the Management of Soft Tissue Sarcomas 2016/2024</u>
17 Sep 2025	Mrs. Laura Ghanem	<u>Efficacy and Safety of Imiquimod 5% for Lentigo Maligna of the Head, Neck & Face: A Systematic Review and Meta-analysis</u>

Notable Presentations Information At EADV 2025

Oncology & Skin Cancers (2/3)



Date	Author	Title
17 Sep 2025	Dr. Michael Migden	<u>Trial in progress: A phase 3 randomised study of low-dose intralesional cemiplimab versus primary surgery for patients with early-stage cutaneous squamous cell carcinoma</u>
17 Sep 2025	Dr. Sandy Anderson	<u>Real World Performance of a Commercial Deep Neural Network Algorithm in Diagnosing Skin Cancer: Results from the AISCSS Study</u>
17 Sep 2025	Dr. Clare Primiero	<u>3D Total-Body Photography in Patients at High Risk for Melanoma. A Randomized Clinical Trial</u>
17 Sep 2025	Dr. Matteo Crivellari	<u>Evaluation of the benefits of Urea 30% emollient cream prior to PDT in AK treatment: results of a split scalp RCT</u>
17 Sep 2025	Mrs. Laura Ghanem	<u>Efficacy and safety of photodynamic therapy with or without 5-fluorouracil pretreatment for actinic keratosis: A systematic review and meta-analysis of randomized controlled trials</u>
17 Sep 2025	Dr. Emilio Garcia-Mouronte	<u>Efficacy and Tolerability of Two Low-Irradiance Red Light Photodynamic Therapy Regimens in Actinic Keratosis of the Head and Scalp: A Clinical Trial with BF-200 ALA</u>
17 Sep 2025	Mrs. Alexandra Sjöholm	<u>A randomized trial comparing simulated daylight and conventional photodynamic therapy in the treatment of clinically diagnosed superficial basal cell carcinoma</u>
17 Sep 2025	Dr. Andrea Agostini	<u>Efficacy and tolerability of tirbanibulin 1% ointment in basal cell carcinoma: real-life experience in Italy</u>

Notable Presentations Information At EADV 2025

Oncology & Skin Cancers (3/3)



Date	Author	Title
17 Sep 2025	Prof. Dr. Rolf-Markus Szeimies	<u>Sun exposure monitoring by ultraviolet sensor in patients with actinic keratosis treated with tirbanibulin 10 mg/g ointment or diclofenac sodium 3% gel: a Phase IV randomized study</u>
17 Sep 2025	Prof. Dr. Julia Welzel	<u>Tirbanibulin Ointment 1% over a Treatment Field up to 100 cm2 in Actinic Keratosis: A Phase 3 Study</u>
17 Sep 2025	MD Andrew Blauvelt	<u>Safety and tolerability of tirbanibulin for the treatment of actinic keratosis: Results from clinical trials and post-registration</u>
17 Sep 2025	Dr. Neal D Bhatia	<u>Clearance of actinic keratosis with tirbanibulin: Comparing results from controlled trials with real-world/low interventional clinical studies</u>
17 Sep 2025	Mrs. Alexandra Sjöholm	<u>A randomized trial comparing simulated daylight and conventional photodynamic therapy for the treatment of actinic keratoses.</u>

Notable Presentations Information At EADV 2025

Other Autoimmune & Rare Dermatoses (1/3)



Date	Author	Title
17 Sep 2025	Prof. Dr. omar boudghene stambouli	Rapamycin trial in a historical case of Maffucci syndrome
17 Sep 2025	Dr. Safa Gueroum	Efficacy of sirolimus in blue rubber bleb nevus syndrome
17 Sep 2025	MD, PhD laura mateu-arrom	Efficacy and Safety of Low-Dose Rituximab in Pemphigus Vulgaris and Foliaceus: A Case Series in Routine Clinical Practice
17 Sep 2025	Dr. Victoria Werth	Efficacy and safety of deucravacitinib in patients with discoid lupus erythematosus (DLE) and/or subacute cutaneous lupus erythematosus (SCLE): results from PAISLEY CLE, a global, phase 2 randomized, double-blind, placebo-controlled trial
17 Sep 2025	PhD Peng Gu	Discovery and characterization of SIM0711, a potent and selective IRAK4 PROTAC with Enhanced Efficacy and Safety
17 Sep 2025	Dr. Ishita Kaushal	Assessment of efficacy of a combination of low dose rituximab and low dose prednisolone vs low dose prednisolone alone in inducing repeat remission in rituximab treated pemphigus vulgaris patients who develop disease relapse: A randomised controlled trial
17 Sep 2025	Dr. Victoria Werth	Efficacy and safety of first-in-class oral small molecule toll-like receptor 7/8 inhibitor enpatoran in patients with lupus erythematosus and active cutaneous manifestations: Results of the Phase II WILLOW study
17 Sep 2025	Prof. Dr. RAJU CHAUDHARY	Comparative Efficacy and Safety of 500 mg versus 1000 mg Rituximab in Pemphigus Vulgaris

Notable Presentations Information At EADV 2025

Other Autoimmune & Rare Dermatoses (2/3)



Date	Author	Title
17 Sep 2025	Dr. Sudip Parajuli	<u>Efficacy and safety of rituximab therapy in immunobullous diseases: Experience from a cohort treated at a tertiary care center in ..</u>
17 Sep 2025	PhD Peng Gu	<u>SIM0708, an antibody-drug conjugate (ADC) with half-life extended anti-IL-4 receptor a (IL-4Ra) antibody and glucocorticoid receptor modulator exhibits superior efficacy treating inflammatory diseases</u>
17 Sep 2025	Dr. Paridhi Vaidh	<u>Rituximab in Pemphigus Vulgaris: A retrospective study evaluating dosing impact on treatment efficacy and infections in a tuberculosis endemic region</u>
17 Sep 2025	Dr. Monica Li	<u>Laser Therapies in Cutaneous Mastocytosis: A Systematic Review of Efficacy and Safety</u>
17 Sep 2025	Mrs. Felicia Thianich	<u>Safety and Quality of Life Outcomes in Randomized Controlled Trials of Pharmacologic Treatments for Cutaneous Sarcoidosis: A Systematic Review and Meta-Analysis</u>
17 Sep 2025	Mrs. Megha Udupa	<u>The Efficacy of Dupilumab in Lichen Planus and Characteristics of Dupilumab-Induced Lichenoid Drug Eruption: A Systematic Review</u>
17 Sep 2025	Dr. Shi Yan	<u>Memory B cells from patients with Netherton syndrome caused by SPINK5 loss-of-function exhibit suppressed early B cell receptor activation resulting in impaired antibody production</u>
17 Sep 2025	Dr. Dr. Aishwarya Muddebihal	<u>Baricitinib in Refractory Generalized Granuloma Annulare: Variable Therapeutic Efficacy and the Importance of Type-Specific Cytokine Profiling</u>

Notable Presentations Information At EADV 2025

Other Autoimmune & Rare Dermatoses (3/3)



Date	Author	Title
17 Sep 2025	Dr. med. Alireza Jafarzadeh	<u>Advances in the treatment of pyoderma gangrenosum: Efficacy and safety of small molecule inhibitors and interleukin inhibitors: a systematic review</u>
17 Sep 2025	Dr. Alex Ortega Loayza	<u>Baricitinib in the Treatment of Adults with Pyoderma Gangrenosum: A Phase II Open Label Trial</u>
19 Sep 2025	Dr. Melanie Chin	<u>Results from the HELIOS Study: A Phase 2, Open-label, Long-term Extension Study of Bitopertin in Erythropoietic Protoporphyria</u>

Notable Presentations Information At EADV 2025

Pediatric Dermatology & Regenerative Medicine (1/3)



Date	Author	Title
17 Sep 2025	Prof. Dr. Olga Bogomolets	<u>Comparative Efficacy of 1% Timolol in Treating Infantile Hemangiomas with Deep Growth Tendencies: Topical Application vs. Occlusive Compresses</u>
17 Sep 2025	Dr. waseem SAAD	<u>The efficacy and safety of Beta-Blockers in Infantile Hemangioma: a retrospective cohort study.</u>
17 Sep 2025	Dr. Ayush Jain	<u>An observational-phase clinical trial for intralesional radiofrequency ablation in the treatment of slow flow vascular malformations</u>
17 Sep 2025	MD Kachanat Phansuk	<u>Efficacy and safety of polynucleotide injection for the treatment of hypertrophic scars and keloids on abdomen: a randomized, double-blinded, split-scar study</u>
17 Sep 2025	MD Michał Niedźwiedź	<u>Patch Test Results in Pediatric Patients with Suspected Contact Dermatitis: A Single-Center Study</u>
17 Sep 2025	PhD Suzanne Keddie	<u>Findings from phase 1 and 2 of the EPISTAR study: harmonising epidemiological research methods for atopic dermatitis</u>
17 Sep 2025	MD, PhD Thusanth Thuraisingam	<u>Efficacy and Tolerability of a Selenium Disulfide Shampoo in Pediatric Population with Mild-to-Moderate Dandruff and Seborrheic Dermatitis</u>
17 Sep 2025	MD Joseph Yardman-Frank	<u>A global assessment of barriers to dermatologic care and underserved populations: international survey results from the SkinObservatory Study</u>

Notable Presentations Information At EADV 2025

Pediatric Dermatology & Regenerative Medicine (2/3)



Date	Author	Title
17 Sep 2025	MD Esranur Ünal	<u>Efficacy of Topical 2% Carteolol in the Treatment of Infantile Hemangiomas: A Dermoscopic and Clinical Evaluation</u>
17 Sep 2025	Dr. Mishari Alrubaiaan	<u>Efficacy and Safety of Combined Pulsed Dye laser and Propranolol vs. Monotherapy with Pulsed Dye Laser or Propranolol for Infantile Hemangioma: A Systematic Review and Meta-Analysis</u>
17 Sep 2025	Dr. Brocario Alexia	<u>Tolerance and efficacy of a spray containing Rhealba oat and zinc oxide in reducing symptoms of non-severe and uncomplicated chickenpox in infants and children</u>
17 Sep 2025	Dr. PhD Valérie MENGEAUD	<u>Evaluation of the tolerance and efficacy of a shampoo and a spray containing polidocanol in patients with anti-cancer treatment and suffering of trichodynia and scalp discomfort sensations</u>
17 Sep 2025	PhD Wen-Kai Hsiao	<u>A Balancing Act – Optimizing Efficacy vs. Safety with Time-Resolved Tissue-Level PK Data</u>
17 Sep 2025	Dr. Aline STENNEVIN	<u>Tolerance and Efficacy of a Massage Gel in Adults and Adolescents with recent and Red Scars</u>
17 Sep 2025	Dr. med. Alireza Jafarzadeh	<u>Effect of Topical Timolol on Healing of Immature Breast Scars After Mammoplasty: A Randomized Controlled Trial with Blinded Assessors and Patients</u>
17 Sep 2025	Dr. Sami Salahia	<u>Comparative efficacy of different types of Exosomes as Small extracellular vesicles (sEVs) in wound healing: A Network Meta-Analysis</u>

Notable Presentations Information At EADV 2025

Pediatric Dermatology & Regenerative Medicine (3/3)



Date	Author	Title
17 Sep 2025	Dr. Arash Mostaghimi	<u>Randomised Phase 3 trial of spesolimab in patients with ulcerative pyoderma gangrenosum: A study protocol</u>
17 Sep 2025	Dr. med. Alireza Jafarzadeh	<u>A systematic review of procedural treatments for burn scars in children: Evaluating efficacy, safety, standard protocols, average sessions and tolerability based on clinical studies</u>
17 Sep 2025	Dr. med. Alireza Jafarzadeh	<u>The efficacy, satisfaction, and safety of carbon dioxide (CO2) fractional laser in combination with pulsed dye laser (PDL) versus each one alone in the treatment of hypertrophic burn scars: a single-blinded randomized controlled trial</u>
17 Sep 2025	Dr. med. Alireza Jafarzadeh	<u>A systematic review of the efficacy, safety and satisfaction of regenerative medicine treatments, including platelet-rich plasma, stromal vascular fraction and stem cell-conditioned medium for hypertrophic scars and keloids</u>
17 Sep 2025	Dr. Afsaneh Alavi	<u>Dose and time dependent efficacy of vilobelimab on wound healing outcomes in patients with ulcerative pyoderma gangrenosum – findings from a Phase 2 trial</u>

Notable Presentations Information At EADV 2025

Prurigo Nodularis, Chronic Pruritus & Urticaria (1/4)



Date	Author	Title
17 Sep 2025	Dr. Bichra Amina	<u>Systematic review and meta-analysis of the efficacy and risk of adverse events of dupilumab in the treatment of prurigo nodularis</u>
17 Sep 2025	Assoc. Prof. hicham titou	<u>The efficacy and safety of nemolizumab in patients with prurigo nodularis: A systematic review and meta-analysis of randomized controlled trials</u>
17 Sep 2025	MD Francisco Javier León Pérez	<u>Efficacy and Safety of Dupilumab in Prurigo Nodularis: 48-Week Real-World Clinical Practice Experience.</u>
17 Sep 2025	Dr. Svenja Royeck	<u>Perceived Stress in Chronic Pruritus: Results of A Prospective Cohort Study in Atopic Dermatitis, Chronic Prurigo, and Chronic Pruritus on Non-Lesional Skin</u>
17 Sep 2025	Dr. Donia Bahloul	<u>Dupilumab Improves Prurigo Activity and Severity in Patients with Prurigo Nodularis: Pooled Results from the PRIME and PRIME2 Trials</u>
17 Sep 2025	Dr. Donia Bahloul	<u>Sleep Disturbance and Quality of Life Impact in Patients with Prurigo Nodularis in Europe: Results from the PN – paTient Reported burdEn of sickNess (PN-TREK) Study</u>
17 Sep 2025	Dr. Donia Bahloul	<u>Mental Health Burden in Prurigo Nodularis: Results from the PN- paTient Reported burdEn of sickNess (PN-TREK) EU Real-World Study</u>
17 Sep 2025	Dr. Donia Bahloul	<u>Skin Pain in Patients with Prurigo Nodularis: Results from the Real-World Patient Survey: PN-TREK EU Study</u>

Notable Presentations Information At EADV 2025

Prurigo Nodularis, Chronic Pruritus & Urticaria (2/4)



Date	Author	Title
17 Sep 2025	MD Lian van der Gang	Real-world efficacy and safety of dupilumab in prurigo nodularis: 52-week results from the BioDay registry
17 Sep 2025	Dr. Kashif Bhatti	Variation in CSU management practices between dermatology and immunology/allergy – results from the REVEAL UK survey
17 Sep 2025	Dr. Alhasan Altayf	Efficacy and safety of remibrutinib in chronic spontaneous urticaria : a systematic review and meta-analysis
17 Sep 2025	Thomas Casale	Dupilumab Provides Early and Sustained Improvement in Itch in Patients With Chronic Spontaneous Urticaria: Pooled Results From LIBERTY-CSU CUPID Study A and Study C
17 Sep 2025	Dr. Jitesh Rai	Dupilumab Efficacy Regardless of Baseline Total Serum IgE Levels: Results from the Pooled LIBERTY-CSU CUPID Study A and Study C
17 Sep 2025	Sakina Baig	Dupilumab Provides Early and Sustained Improvement in Urticaria Activity in Patients With Chronic Spontaneous Urticaria: Pooled Results From LIBERTY-CSU CUPID Study A and Study C
17 Sep 2025	Dr. Osman Haji	Evaluating the efficacy of omalizumab in urticaria resistant to anti-histamines
17 Sep 2025	Prof. Dr. Martin Metz	BLU-808, a potent and selective inhibitor of wild-type KIT, in patients with chronic inducible urticaria and chronic spontaneous urticaria: trial-in-progress

Notable Presentations Information At EADV 2025

Prurigo Nodularis, Chronic Pruritus & Urticaria (3/4)



Date	Author	Title
17 Sep 2025	Prof. Ana Giménez-Arnau	<u>REMIX-1/-2: Long-term efficacy of remibrutinib in patients with CSU from the European region</u>
17 Sep 2025	Dr. Yashdeep Pathania	<u>To compare the efficacy and safety of cyclosporine versus azathioprine in the treatment of refractory Chronic Spontaneous Urticaria</u>
17 Sep 2025	Assoc. Prof. Esra Sarac	<u>Medical interventions and aesthetic procedures in patients with chronic spontaneous urticaria: First results of the international, multicenter, case-control RIFA-CU study</u>
17 Sep 2025	Assoc. Prof. Abhishek De	<u>Efficacy of Vitamin D3 Supplementation as an Adjunct to Bilastine 40 mg in Chronic Spontaneous Urticaria Patients with Vitamin D3 Deficiency: A Randomized, Double-Blind, Placebo-Controlled Study</u>
17 Sep 2025	Prof. Dr. Martin Metz	<u>Remibrutinib-treated patients with CSU who achieve well-controlled disease activity reach this by week 3 in the majority of patients: Results from REMIX-1/-2 studies</u>
17 Sep 2025	MD Martin Cevallos Cueva	<u>Safety and efficacy of bruton's tyrosine kinase inhibitors for the treatment of chronic spontaneous urticaria: a systematic review and meta-analysis of randomized controlled trials</u>
17 Sep 2025	Merin Kuruvilla	<u>Impact of Early vs Late Biologic Treatment Initiation on Health Care Resource Utilization in Patients With Chronic Spontaneous Urticaria: Results From a United States Claims Database Study</u>
17 Sep 2025	Mrs. Grace Xiong	<u>Comparative Efficacy of Omalizumab, Dupilumab, and Remibrutinib in Chronic Spontaneous Urticaria: A Network Meta-Analysis of Randomized Control Trials</u>

Notable Presentations Information At EADV 2025

Prurigo Nodularis, Chronic Pruritus & Urticaria (4/4)



Date	Author	Title
17 Sep 2025	Mr. Sagar Wagh	Efficacy of remibrutinib in patients with CSU by demographics and baseline characteristics: Pooled analysis from REMIX-1/-2 studies
17 Sep 2025	Prof. Dr. Dr. Sonja Ständer	Efficacy and Safety of Ruxolitinib Cream in Patients With Prurigo Nodularis: Pooled Results From the Phase 3 TRuE-PN1 and TRuE-PN2 Randomized, Vehicle-Controlled Studies



Key Industry Sponsored Symposia Information

EADV 2025 Key Industry Sponsored Sessions Information (1/9)



Date	Sponsor	Title
17 Sep 2025	VICHY / L'OREAL	Ageing Science in the Era of Longevity:From Research Discoveries to Practical Solutions.
17 Sep 2025	Sanofi / Regeneron	Bullous Pemphigoid: Insights and Innovation
17 Sep 2025	Novartis	PsO in a New Light: Exploring the Opportunities of Early Intervention
17 Sep 2025	Johnson & Johnson	Sculpting optimal psoriasis care: the earlier the better?
17 Sep 2025	Kenvue	The Science of Prejuvenation: Addressing a Generational Shift in Early Skin Care
17 Sep 2025	Regeneron	Treatment Advances in Cutaneous Squamous Cell Carcinoma at Risk of Recurrence
17 Sep 2025	Eucerin	Acne treatment now and in the future: Integrating Skin Science and Microbiome Care

EADV 2025 Key Industry Sponsored Sessions Information (2/9)



Date	Sponsor	Title
17 Sep 2025	Roche	Dermatology in a changing world: a 50-years outlook
17 Sep 2025	Shanghai CHICMAX Cosmetic	Novel Discoveries and Treatment Technologies Targeting the Chinese Skin Type
17 Sep 2025	DERMALOGICA PRO	New form of exosomes with human level efficacy
17 Sep 2025	Laboratoire SVR	The impact of endocrine disruptors: a reality in everyday dermatological practice
18 Sep 2025	Incyte	A new frontier in HS: Spotlight on the JAK-STAT pathway
18 Sep 2025	Alpenglow Biosciences	Beyond the Slide: AI-Enhanced 3D Mapping Illuminates Hidden Skin Architecture
18 Sep 2025	Kenvue	The Regenerative Power of Oat: Clinical Evidence Meets Human Story



EADV 2025 Key Industry Sponsored Sessions Information (3/9)



Date	Sponsor	Title
18 Sep 2025	Johnson & Johnson	A clinical rendezvous in Paris: practical approaches to complex psoriasis cases
18 Sep 2025	Dexeryl	The Art of Simplicity: Dermocosmetic Acne solutions through minimalism
18 Sep 2025	AVENE – PIERRE FABRE DERMO COSMETIQUE	A paradigm shift in atopy management: redefining the patient journey
18 Sep 2025	Novartis	Unlocking the Immune Puzzle of Hidradenitis Suppurativa: Spotlight on BTK Signalling
18 Sep 2025	Eli Lilly	Achieving Optimal Outcomes for Your Adolescent Patients With Alopecia Areata: From Principles to Clinical Practice
18 Sep 2025	Novartis	Breaking free from the burden of CSU: New frontiers in patient care
18 Sep 2025	LEO Pharma	Breaking the cycle: Innovations in Chronic Hand Eczema management



EADV 2025 Key Industry Sponsored Sessions Information (4/9)



Date	Sponsor	Title
18 Sep 2025	Eucerin	<u>Bridging gaps in Hyperpigmentation treatment: The Global Consensus on the Management of Hyperpigmentation</u>
18 Sep 2025	UCB	<u>Does inflammation control set the stage for disease modification in psoriasis?</u>
18 Sep 2025	L'OREAL	<u>Insights into Dermatological Challenges: New Solutions for Androgenetic Alopecia, Mature Xerosis Management, and UV induced pigmentary disorders</u>
18 Sep 2025	AbbVie	<u>New horizons in dermatology: Targeting high-impact areas in psoriasis through selective IL-23 modulation</u>
18 Sep 2025	Johnson & Johnson	<u>The art of precision: advancing the era of oral therapies in psoriasis</u>
18 Sep 2025	AVENE – PIERRE FABRE DERMOCOSMETIQUE	<u>The changing epidemiology of acne: from early onset to late persistence</u>
18 Sep 2025	Pfizer	<u>The Future of Alopecia Areata Management: Clinical Insights and Patient Perspectives</u>



EADV 2025 Key Industry Sponsored Sessions Information (5/9)



Date	Sponsor	Title
18 Sep 2025	Sanofi	The Next Paradigm in Atopic Dermatitis: how will future therapies redefine treatment goals?
18 Sep 2025	Galderma	A holistic approach to acne and acne sequelae: Combining retinoids, CTMP™ and cosmetic corrective procedures
18 Sep 2025	Boehringer Ingelheim	What's NEWtrophilic in Chronic Inflammatory Skin Diseases?
18 Sep 2025	CeraVe	Lessons Learned from Utilizing and Implementing a Clinical Decision Support System for Dermatology for Education and Clinical Care.
18 Sep 2025	Medscape Education Global	Personalizing the Care of Patients With Atopic Dermatitis and Head and Neck Involvement
18 Sep 2025	Rilastil	Spotting the danger: prevention and diagnosis of Melanoma and Non Melanoma Skin Cancer
18 Sep 2025	Laboratoire Dermatologique ACM	Unlocking the Future of Hyperpigmentation Management: Latest Advances and a Breakthrough Approach



EADV 2025 Key Industry Sponsored Sessions Information (6/9)



Date	Sponsor	Title
18 Sep 2025	Regeneron	Enhancing Impactful Patient-Centered Care for NMSC Through Meaningful Connections
18 Sep 2025	Celltrion	Getting to Know Biosimilars in Chronic Spontaneous Urticaria
18 Sep 2025	Almirall	Psoriasis: is there anything left to solve?
18 Sep 2025	Novartis	HS in a new light: Advancing disease management together
19 Sep 2025	AbbVie	New horizons in dermatology: Shaping the future of alopecia areata and vitiligo
19 Sep 2025	AVENE – PIERRE FABRE DERMO COSMETIQUE	Aesthetic journey: The best dermocosmetic protocol for maximized clinical results
19 Sep 2025	ADERMA – PIERRE FABRE DERMO COSMETIQUE	ATOPIC DERMATITIS: An immersion into a Patient's Night



EADV 2025 Key Industry-Sponsored Sessions Information (7/9)



Date	Sponsor	Title
19 Sep 2025	Medscape	Challenges and Opportunities in the Management of CHE: Key Considerations for Clinical Practice
19 Sep 2025	DUCRAY – PIERRE FABRE DERMO COSMETIQUE	LABORATOIRES DERMATOLOGIQUES DUCRAY – PIERRE FABRE DERMO COSMETIQUE
19 Sep 2025	Galderma	Sensitive skin syndrome: A rising phenomenon linked to modern lifestyles and environmental changes
19 Sep 2025	Boehringer Ingelheim	A Glimpse into Life With GPP: Understanding the Chronic Patient Burden and Role of Targeted Continuous Treatment
19 Sep 2025	Incyte	Bridging the gap: Evolving moderate AD care
19 Sep 2025	UCB	Charting the future of HS care through inflammation control
19 Sep 2025	Eli Lilly	Dermatology Unscripted: How real-world insights are shaping clinical practice in alopecia areata, plaque psoriasis, and atopic dermatitis



EADV 2025 Key Industry Sponsored Sessions Information (8/9)



Date	Sponsor	Title
19 Sep 2025	Galderma	<u>Ditching the itch: Exploring the latest advances in atopic dermatitis and prurigo nodularis, targeting freedom from itch and long-term skin lesion control</u>
19 Sep 2025	Almirall	<u>Long-term control in Atopic Dermatitis: Elevating Therapeutic Goals</u>
19 Sep 2025	BIODERMA	<u>Management of Rosacea : for a better patient's outcome</u>
19 Sep 2025	AbbVie	<u>New horizons in dermatology: Achieving minimal disease activity with JAK inhibition in atopic dermatitis</u>
19 Sep 2025	Sanofi / Regeneron	<u>The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of AD?</u>
19 Sep 2025	BMS	<u>Unified strategies in Psoriatic Disease: Dermatology and Rheumatology perspectives</u>
19 Sep 2025	Roche	<u>Invisible scars: the lasting impact of atopic dermatitis through a landmark epidemiological study</u>



EADV 2025 Key Industry Sponsored Sessions Information (9/9)



Date	Sponsor	Title
19 Sep 2025	SkinCeuticals	The Power of C E Ferulic
19 Sep 2025	Incyte	Two years on: How ruxolitinib cream is shaping the practical management of vitiligo
19 Sep 2025	Eucerin	Epigenetic breakthroughs in reversing biological age for skin longevity: on all skin tones and in combination with aesthetic treatments
19 Sep 2025	Unilever	From Cells to Sales: Personalised Scalp Care
19 Sep 2025	Sanofi / Regeneron	Broadening the Lens: Clinical and Immunological Insights that Inform CSU Management
19 Sep 2025	Amgen / Kyowa Kirin	Rebalancing the future: OX40R and a new era of atopic dermatitis treatment
20 Sep 2025	Sanofi	The Tipping Point: Where HS Burden Meets Breakthrough







Themes from key AI / ML presentations at EADV 2025 (1/3)

- **AI and machine learning are poised to revolutionize dermatology by enhancing diagnostic accuracy, personalizing treatment plans, and improving disease management across various skin conditions, while addressing ethical and equity challenges**
- Check out the key AI / ML themes at EADV 2025 below:
- **Acne Diagnosis & Severity Assessment:**
 - AI-based methods for evaluating acne severity will focus on deep learning and image analysis, assessing inflammatory lesions and their density
- **Hidradenitis Suppurativa Diagnosis:**
 - AI algorithms leveraging real-world registry data will enhance the identification and diagnosis of hidradenitis suppurativa, improving efficiency
- **Alopecia Areata & Hair Regrowth:**
 - AI-discovered GPCR19 agonists will promote hair regrowth in alopecia areata by expanding regulatory T cells and restoring immune privilege



Themes from key AI / ML presentations at EADV 2025 (2/3)

- **Pigmented Lesion Classification:**

- Deep learning techniques will be explored for facial pigmented lesion classification, aiding laser treatment planning through AI-assisted diagnostics

- **Skin Cancer Detection:**

- AI-powered tools, including smartphone apps and diagnostic accuracy studies, will aid in skin cancer detection, focusing on melanoma, basal cell carcinoma, and non-melanoma skin cancers

- **Artificial Intelligence in Non-Melanoma Skin Cancer:**

- Machine learning models will improve diagnostic accuracy in non-melanoma skin cancer, integrating interferon alfa 2b and gamma treatments

- **Artificial Intelligence in Psoriasis:**

- AI-based predictive models will personalize psoriasis treatment, predicting treatment outcomes and disease progression



Themes from key AI / ML presentations at EADV 2025 (3/3)

- **Machine Learning for Melanoma Diagnosis:**
 - AI models in melanoma diagnosis will integrate clinical and histopathological imaging, enhancing diagnostic efficiency
- **AI in Chronic Skin Diseases:**
 - Machine learning techniques will analyze chronic skin disease patient data, focusing on real-world characteristics, comorbidities, and treatment insights
- **Machine Learning in Atopic Dermatitis:**
 - AI tools for evaluating and scoring atopic dermatitis severity using deep learning frameworks will contribute to clinical practice
- **AI-Assisted Dermatology Education:**
 - AI-powered tools like Suno will be explored for teaching dermatology through innovative, song-based methods
- **Ethical and Equity Considerations in AI:**
 - Ethical implications of AI in dermatology will be discussed, focusing on biases in machine learning datasets and the importance of equitable AI integration across diverse skin types



Noteworthy AI / ML presentations at EADV 2025

Notable Presentations Information At EADV 2025

AI / ML (1/9)



Date	Author	Title
17 Sep 2025	Mrs. Léa Gazeau	AcneAI: A new acne severity assessment method using digital images and deep learning
17 Sep 2025	MD Elio Assaad Saad	From Breakouts to Breakthroughs: How Artificial Intelligence is Revolutionizing Acne Diagnosis, Classification, and Management.
17 Sep 2025	Alexander Kahanek	Identifying Hidradenitis Suppurativa Using AI and Real-World Registry Data
17 Sep 2025	Mr. Alfonso Medela	Automatic evaluation, based on artificial intelligence, of acne severity by counting inflammatory lesions and their density
17 Sep 2025	Mr. Kenichi Yamanaka	Development and Utility Investigation of Educational Artificial Intelligence (AI) Software for Atopic Dermatitis Severity Assessment
17 Sep 2025	Mr. Sunwoong Hong	Artificial Intelligence-Discovered GPCR19 Agonist Promotes Hair Regrowth by Expanding Regulatory T Cells and Restoring Hair Follicle Immune Privilege in Alopecia Areata
17 Sep 2025	MD keiko watanabe	AI-assisted Classification of Facial Pigmented Lesions for Laser Treatment Planning: A Deep Learning-based Comparative Study

Notable Presentations Information At EADV 2025

AI / ML (2/9)



Date	Author	Title
17 Sep 2025	Dr. med. Nan Huang	Advancing cosmetics adverse reaction prediction and responsible ingredients identification in the big data era by machine learning
17 Sep 2025	MD Irina Poleva	The Role of Artificial Intelligence in Aesthetic Medicine
17 Sep 2025	MD Waritsara Piyanonpong	Development of artificial intelligence model and comparison of performance between artificial intelligence and physicians in the diagnosis of common epidermal tumors
17 Sep 2025	Mr. Garrett Kraft	A melanoma-specific classifier employing elastic scattering spectroscopy and machine learning to evaluate suspicious skin lesions
17 Sep 2025	Dr. Christian Dorado Cortez	Application of Raman Confocal Microspectroscopy Guided by LC-OCT for AI Supervised Chemical Characterization of Basal Cell Carcinoma
17 Sep 2025	Dr. Joshua Luck	Use of a CE Class III Artificial Intelligence as a Medical Device in community-based diagnostic hubs to increase the detection rate of high risk skin cancers - a prospective, multi-centre clinical evaluation.
17 Sep 2025	Yongyi Xie	Clinically Inspired Dual-Stage AI Framework for Resource-Efficient Melanoma Diagnosis: Integrating Clinical and Histopathological Imaging

Notable Presentations Information At EADV 2025

AI / ML (3/9)



Date	Author	Title
17 Sep 2025	PhD Catherine Silotch	<u>Environmental and Neighborhood Predictors of Systemic Sclerosis Incidence: A Population-Based Machine Learning Study</u>
17 Sep 2025	Prof. Dr. Linda Tognetti	<u>Design and development of a systematic validation protocol for synthetic melanoma images for a responsible use in medical Artificial Intelligence</u>
17 Sep 2025	Dr. Amanda Kuan	<u>Deep Learning for Diagnosis of Basal Cell Carcinoma Using Reflectance Confocal Microscopy – Tertiary Center Experience</u>
17 Sep 2025	Mrs. Zaina Chaudhry	<u>Racial Bias in AI-Powered Dermatology Tools: Underrepresentation of Skin of Color in Machine Learning Datasets</u>
17 Sep 2025	Dr. meryem el bakkali	<u>Beyond the Algorithm: How Young Dermatologists Perceive and Embrace Artificial Intelligence in Clinical Practice</u>
17 Sep 2025	Dr. Julie Kips	<u>Artificial intelligence-based smartphone app for skin cancer detection: a prospective diagnostic accuracy study</u>
17 Sep 2025	PhD Susely Figueroa Iglesias	<u>Artificial Intelligence in the diagnosis of non-melanoma skin cancer and treatment with the combination of interferon alfa 2b and gamma</u>

Notable Presentations Information At EADV 2025

AI / ML (4/9)



Date	Author	Title
17 Sep 2025	MD María Ribagorda	Improving diagnostic accuracy in dermatology through Artificial Intelligence: A Pilot study in Primary Care
17 Sep 2025	MD Tishya Mukherjee	Artificial Intelligence in Dermatology: Trends, Challenges, and the AI Integration Ladder Framework
17 Sep 2025	Dr. Marian Rivas-Calderon	Characterization of patients with large/giant congenital melanocytic nevus through the body surface area affected by nevus and satellites using 3D total body photography with deep learning tools: Risk quantification of neurocutaneous complications.
17 Sep 2025	Dr. Pietro Scribani Rossi	Therapeutic Efficacy Evaluation of Imiquimod 5% Cream in Patients with Superficial Basal Cell Carcinomas by Line-Field Confocal Optical Coherence Tomography combined with Artificial Intelligence
17 Sep 2025	Mr. Ethan Bendayan	Evaluation of Artificial Intelligence Chatbots in Assisting Genetic Counselors in Genodermatology
17 Sep 2025	Dr. Ricardo Ruiz-Villaverde	Differential Involvement of CD4+ and CD8+ Lymphocytes in Frontal Fibrosing Alopecia: An Immunohistological and Machine Learning Approach
17 Sep 2025	Dr. Pattriya Jirawattanadon	Sensitivity and Specificity of a Deep Learning Model in the Diagnosis of Onychomycosis Using Hyponychium and Dorsal Nail Views

Notable Presentations Information At EADV 2025

AI / ML (5/9)



Date	Author	Title
17 Sep 2025	MD María Ribagorda	An Automated Assessment of Female Androgenic Alopecia Based on Artificial Intelligence
17 Sep 2025	Prof. Dr. Patricia Deps	External validation of the WHO skin NTDs App's artificial intelligence algorithms for diagnosing leprosy and leprosy reactions
17 Sep 2025	MD Raquel Rivera Díaz	Analysis of the mortality rate associated with inflammatory skin diseases in patients attending tertiary hospitals in Spain, using artificial intelligence: DERMACLEAR study.
17 Sep 2025	Dr. Flaminia Antonelli	Identifying clinical predictive response factors to adalimumab in HS patients: human traditional analytics versus AI clustering
17 Sep 2025	Dr. Eduardo Deliyannis	Breaking barriers: using to AI replicate inflammatory skin conditions in non-white complexions.
17 Sep 2025	Dr. Bladimir Lechtig	Teaching Dermatology with Songs: An Artificial Intelligence-Based Approach to Medical Education Using Suno
17 Sep 2025	PhD Helene Duplan	Development of a protein-clock for estimating biological age in the epidermis using machine learning: insights from the INSPIRE-T cohort

Notable Presentations Information At EADV 2025

AI / ML (6/9)



Date	Author	Title
17 Sep 2025	Dr. Monisha Madhumita	Machine Learning-Based Prediction of Treatment Outcomes and Recurrence Risk in Melasma Using High-Resolution Imaging Data
17 Sep 2025	PhD Eduard Sarró	Real-World Characteristics, Comorbidities, and Treatment of Psoriasis Patients in Spain: A Multicenter Study Using Natural Language Processing and Machine Learning
17 Sep 2025	Dr. Elena Netchiporouk	Environmental and Socioeconomic Determinants of Psoriasis Risk: A Machine Learning Study Using the Canadian CanPath Cohort
17 Sep 2025	PhD Rebecca Santorella	Using AI to Predict Progression from Psoriasis to Psoriatic Arthritis in a Real-World Dataset
17 Sep 2025	PD Dr. med. Victor Olsavszky	Automated Machine Learning for Chronic Skin Disease Patient Data Analysis
17 Sep 2025	Dr. Emily Pender	Personalising psoriasis treatment using artificial intelligence predictive models – a pilot study.
17 Sep 2025	Mr. Taig Mac Carthy	Artificial Intelligence-Based Quantification to Evaluate Automatic Psoriasis Area and Severity Index

Notable Presentations Information At EADV 2025

AI / ML (7/9)



Date	Author	Title
17 Sep 2025	MD Andreja Pagon	Echoes of infestation: how I told the AI about the bugs
17 Sep 2025	Dr. Bouchra Idrissi Rhenimi	Artificial Intelligence in Dermatology: Tool, Ally, or Threat? A Survey among Medical and Paramedical Staff
17 Sep 2025	Dr. Josep Malvehy	Artificial Intelligence in melanoma screening: From mobile apps to total body dermoscopy
17 Sep 2025	Prof. Jean François Stalder	Analysis of the survey on the role of artificial intelligence in the management of atopic dermatitis
17 Sep 2025	Dr. April Armstrong	Pixels and plaques: Artificial Intelligence in psoriasis
18 Sep 2025	Dr. PhD Kenneth Thomsen	Can AI provide reliable treatment and care advice?
18 Sep 2025	Patricia Duarte Deps	External validation of the WHO skin NTDs App's artificial intelligence algorithms for diagnosing leprosy and leprosy reactions

Notable Presentations Information At EADV 2025

AI / ML (8/9)



Date	Author	Title
18 Sep 2025	Prof. Alexander Navarini	Stop Typing: Let AI do it for you!
18 Sep 2025	Prof. Harald Kittler	Stop Thinking: Let AI think for you!
18 Sep 2025	Prof. Dr. Dr. Philipp Tschandl	Stop Searching: Let AI search for you!
18 Sep 2025	Prof. Alexander Navarini	Stop calculating: Let AI calculate for you!
18 Sep 2025	Prof. Dr. Dr. Philipp Tschandl	Stop Looking: Let AI look for you!
18 Sep 2025	Mr. Ethan Bendayan	Evaluation of Artificial Intelligence Chatbots in Assisting Genetic Counselors in Genodermatology
18 Sep 2025	Dr. Jui Vyas	Artificial intelligence in dermatology: Navigating ethics and equity

Notable Presentations Information At EADV 2025

AI / ML (9/9)



Date	Author	Title
19 Sep 2025	Dr. Sharif Amit Kamran	Interpretable Deep Learning Framework for Automated EASI Scoring in Atopic Dermatitis Assessment
20 Sep 2025	MD Vincenzo Bettoli	Artificial Intelligence to score acne severity

Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM